var title_f36_43_37552="CT image halo";
var content_f36_43_37552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT image halo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 77-year-old female patient with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk. Immediate post-procedure CT image with reactive \"halo\" of ground-glass parenchymal opacity (arrows) surrounding the treatment site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Schirmang, T, MD and Dupuy, D, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37552=[""].join("\n");
var outline_f36_43_37552=null;
var title_f36_43_37553="Sonogram normal fetal foot";
var content_f36_43_37553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of normal fetal foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the foot is normally oriented, the bones of the lower leg and plantar surface of the foot cannot be visualized in the same plane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Urania Magriples, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37553=[""].join("\n");
var outline_f36_43_37553=null;
var title_f36_43_37554="Patient information: Medicine brand and generic names (The Basics)";
var content_f36_43_37554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16262\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/39/19066\">",
"         The different parts of a medicine label (Drug Facts)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/37/34395\">",
"          Examples of common brand and generic names",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicine brand and generic names (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicine-brand-and-generic-names-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29401105\">",
"      <span class=\"h1\">",
"       Do prescription medicines go by different names?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A single prescription medicine goes by at least 2 different names in the US: a brand name and the generic name. Non-prescription medicines also go by different names. They are discussed at the end of this article.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401112\">",
"      <span class=\"h1\">",
"       Why does a medicine have a brand name and generic name?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A brand name is a name given by a drug company. Usually the company that discovered the medicine gets to give that medicine its brand name. Drug companies try to come up with brand names that sound good on TV and in magazine ads and are easy for doctors and patients to remember.",
"     </p>",
"     <p>",
"      The very same medicine must also have a generic name.",
"      <strong>",
"      </strong>",
"      The generic name is based on what the drug does or its chemistry. The generic name is often longer and more difficult to say than the brand name&mdash;but it&rsquo;s the same medicine. The generic name is made",
"      <strong>",
"      </strong>",
"      up",
"      <strong>",
"      </strong>",
"      by experts and then approved by the government.",
"     </p>",
"     <p>",
"      Every brand-name medicine also has a generic name. But that does not mean there is a generic copy you can buy for every brand-name medicine. If it is a newer medicine, it may be a &ldquo;brand-only&rdquo; medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401119\">",
"      <span class=\"h1\">",
"       What does &ldquo;brand-only&rdquo; mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When a medicine is new, the drug company that discovered it has a patent, and it is the only company allowed to sell it. Usually newer medicines can only be bought as the brand-name version.",
"      <strong>",
"      </strong>",
"      These are called &ldquo;brand-only&rdquo; because right now they only come as the brand name and there are no generic copies on the market yet.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401126\">",
"      <span class=\"h1\">",
"       What are &ldquo;generic&rdquo; medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Generic medicines are less expensive copies of brand-name medicines. They contain the same active ingredient as the brand-name medicine they copy. Makers of generic medicines must follow the same rules about strength and purity as makers of brand-name medicines.",
"     </p>",
"     <p>",
"      After several years, the patent on a new medicine runs out, and generic copies can be sold. When generic copies are allowed to be sold, you can get the medicine as either the brand-name version (usually sold by the original company that made it) or as one of several generic copies.",
"      <strong>",
"      </strong>",
"      The generic copies are sold for less money than the brand versions, and you will not see them advertised on TV or in magazine ads.",
"      <strong>",
"      </strong>",
"      For examples of the brand and generic names of some commonly used medicines, see this table (",
"      <a class=\"graphic graphic_table graphicRef52676 \" href=\"mobipreview.htm?33/37/34395\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401133\">",
"      <span class=\"h1\">",
"       How can I tell if I have the brand medicine or a generic copy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask the pharmacy where you bought the medicine. You probably won&rsquo;t be able to tell just by looking at the pills or the bottle they came in. You can also find out if a brand-name medicine is also sold as a generic copy at this government Web site:",
"      <a class=\"external\" href=\"file://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm\">",
"       file://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401140\">",
"      <span class=\"h1\">",
"       Will I get a generic medicine instead of a brand name?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If there is a generic version of a brand-name medicine you take, you might be put on the generic automatically. Many insurance providers, including Medicare, will cover only the generic versions of medicines if they exist. But that is not true with all insurance companies, or in every state.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401147\">",
"      <span class=\"h1\">",
"       Do brand and generic medicines look the same?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. The brand and generic copies do not look the same. Even different generic copies of the same medicine look different from each other.",
"     </p>",
"     <p>",
"      To help make sure you are taking the right medicines, learn what your medicines look like. If the medicine you get when you fill a prescription has a different name or does not look the way you expect it to, always ask the pharmacist to explain what the medicine is and what it does. Also ask him or her to go over both the brand name and generic name with you. It can be confusing when a single medicine goes by many names.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401154\">",
"      <span class=\"h1\">",
"       How do I switch to a generic medicine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you would like to save money by buying generics instead of brand-name medicines, ask your doctor or pharmacist if there are generic medicines that could work for you. Speak with your doctor to make sure that any change in your medicine is done safely.",
"     </p>",
"     <p>",
"      Anytime you replace 1 medicine with another, for any reason, make sure you learn what the new medicine looks like and which medicine it is replacing. People sometimes accidentally take the same medicine twice because the brand-name and generic pills look different, and they think they are taking 2 different medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401161\">",
"      <span class=\"h1\">",
"       Do non-prescription medicines also have brand and generic names?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A medicine you buy without a prescription can be sold under many different brand names and many different store brands, even though it has the same medicine in it.",
"      <strong>",
"      </strong>",
"      Take, for example, the common non-prescription pain reliever,",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . Acetaminophen is its generic name in the US. Outside the US, this medicine has a different generic name, paracetamol. Plus, the medicine is sold under many different brand names, such as Tylenol&reg; and Panadol&reg;, and under store brands such as &ldquo;Extra-Strength Pain Relief&rdquo; tablets or &ldquo;No-Aspirin&rdquo; tablets. All of these can contain acetaminophen.",
"     </p>",
"     <p>",
"      Read the generic names on the label of your non-prescription medicines to be sure you are not taking more than 1 product that has the same medicine in it. In the US, the generic names of non-prescription medicine are on the label or box where it says",
"      <strong>",
"       Drug Facts",
"      </strong>",
"      and",
"      <strong>",
"       Active ingredient",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef73468 \" href=\"mobipreview.htm?18/39/19066\">",
"       figure 1",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401311\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/43/37554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16262 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37554=[""].join("\n");
var outline_f36_43_37554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401105\">",
"      Do prescription medicines go by different names?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401112\">",
"      Why does a medicine have a brand name and generic name?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401119\">",
"      What does &ldquo;brand-only&rdquo; mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401126\">",
"      What are &ldquo;generic&rdquo; medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401133\">",
"      How can I tell if I have the brand medicine or a generic copy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401140\">",
"      Will I get a generic medicine instead of a brand name?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401147\">",
"      Do brand and generic medicines look the same?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401154\">",
"      How do I switch to a generic medicine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401161\">",
"      Do non-prescription medicines also have brand and generic names?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401311\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/39/19066\">",
"      The different parts of a medicine label (Drug Facts)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/37/34395\">",
"       Examples of common brand and generic names",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_43_37555="Doripenem: Patient drug information";
var content_f36_43_37555=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doripenem: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"     see \"Doripenem: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10805264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Doribax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9537604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doribax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doripenem or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11941 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37555=[""].join("\n");
var outline_f36_43_37555=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10805264\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537604\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024939\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024941\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024940\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024944\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024945\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024947\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024943\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024948\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024949\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=related_link\">",
"      Doripenem: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_43_37556="Fetal abdominal diameters";
var content_f36_43_37556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Measurement of fetal abdominal diameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial image of the fetal abdomen of a late second trimester fetus. This measurement is taken at the level of the fetal stomach, liver, and umbilical vein. Calipers are used to measure the diameters of the fetal abdomen. These measurements can be averaged, or an abdominal circumference can be calculated. These measurements are used to assess gestational age, and especially, fetal weight.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37556=[""].join("\n");
var outline_f36_43_37556=null;
var title_f36_43_37557="Linear IgA bullous dermatosis on arm";
var content_f36_43_37557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense vesicles and inflammatory plaques are present on the arm. Some lesions demonstrate an annular configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37557=[""].join("\n");
var outline_f36_43_37557=null;
var title_f36_43_37558="Kerleys A lines PA";
var content_f36_43_37558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transfusion reaction due to leukoagglutinins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows so-called Kerley's A lines radiating from the hilar regions into the periphery of the lung on a background of pulmonary edema. The Kerley A lines are 2 to 4 cm in length and represent thickening of the axial interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37558=[""].join("\n");
var outline_f36_43_37558=null;
var title_f36_43_37559="Mercaptopurine: Drug information";
var content_f36_43_37559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mercaptopurine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/4/30789?source=see_link\">",
"    see \"Mercaptopurine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"    see \"Mercaptopurine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Purinethol&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Purinethol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog);",
"     </li>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also consult details concerning dosing in combination regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL): Maintenance:",
"     </b>",
"     Oral: 1.5-2.5 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled ALL dosing",
"      </i>",
"     </b>",
"     (combination chemotherapy; refer to specific reference for combinations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Early intensification (two 4-week courses):",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-14 (Larson, 1995; Larson, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Interim maintenance (12-week course):",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-70 (Larson, 1995; Larson, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Maintenance (prolonged):",
"     </b>",
"     50 mg 3 times/day for 2 years (Kantarjian, 2000; Thomas, 2004)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 years from diagnosis (Larson, 1995; Larson, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute promyelocytic leukemia (APL) maintenance (unlabeled use):",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 1 year (in combination with tretinoin and methotrexate) (Powell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn&rsquo;s disease, remission maintenance or reduction of steroid use (unlabeled use):",
"     </b>",
"     Oral: 1-1.5 mg/kg/day (Lichtenstein, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 50 mg once daily; titrate dose up if clinical remission not achieved or down if leukopenia occurs (Lobel, 2004)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 50 mg (25 mg if heterozygous for TPMT activity) once daily; titrate up to goal of 1.5 mg/kg (0.75 mg/kg if heterozygous for TPMT activity) if WBC &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (and at least 50% of baseline) and LFTs and amylase are stable (Siegel, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 1-1.5 mg/kg/day (Carter, 2004)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remission maintenance: 1.5 mg/kg/day (Danese, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment with concurrent allopurinol:",
"      </i>",
"     </b>",
"     Reduce mercaptopurine dosage to 25% to 33% of the usual dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment in TPMT-deficiency:",
"      </i>",
"     </b>",
"     Not always established; substantial reductions are generally required only in homozygous deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"      see \"Mercaptopurine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also consult details concerning dosing in combination regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL): Maintenance:",
"     </b>",
"     Oral:  1.5-2.5 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled ALL dosing",
"      </i>",
"     </b>",
"     <i>",
"      (combination chemotherapy; refer to specific reference for combinations):",
"     </i>",
"     Adolescents &ge;15 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Consolidation phase:",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 0-27 days (5-week course) (Stock, 2008)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 0-13 and days 28-41 (9-week course) (Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Early intensification (two 4-week courses):",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-14 (Larson, 1995; Larson, 1998; Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Interim maintenance:",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 0-41 (8-week course) (Stock, 2008)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1-70 (12-week course) (Larson, 1995; Larson, 1998; Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Maintenance (prolonged):",
"     </b>",
"     50 mg 3 times/day for 2 years (Kantarjian, 2000; Thomas, 2004)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 years from diagnosis (Larson, 1995; Larson, 1998; Stock, 2008)",
"     <b>",
"      or",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 years (girls) or 3 years (boys) from first interim maintenance (Stock, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      APL maintenance (unlabeled use):",
"     </b>",
"     Oral: Adolescents &ge;15 years: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 1 year (in combination with tretinoin and methotrexate) (Powell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Autoimmune hepatitis (unlabeled use):",
"     </b>",
"     Oral: 1.5 mg/kg/day (in combination with prednisone) (Manns, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment with concurrent allopurinol:",
"      </i>",
"     </b>",
"     Reduce mercaptopurine dosage to 25% to 33% of the usual dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment in TPMT-deficiency:",
"      </i>",
"     </b>",
"     Not always established; substantial reductions are generally required only in homozygous deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to renal decline with age, initiate treatment at the low end of recommended dose range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F193234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The manufacturer's labeling recommends starting with reduced doses in patients with renal impairment to avoid accumulation; however, no specific dosage adjustment is provided. The following adjustments have been used by some clinicians (Aronoff, 2007): Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer every 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F193235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The manufacturer&rsquo;s labeling recommends considering a reduced dose in patients with hepatic impairment; however, no specific dosage adjustment is provided.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purinethol&reg;: 50 mg [DSC] [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3878121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preferably on an empty stomach (1 hour before or 2 hours after meals)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For the treatment of ALL in children (Schmiegelow, 1997): Administration in the evening has demonstration superior outcome; administration with food did not significantly affect outcome.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment component of acute lymphoblastic leukemia (ALL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3031909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Steroid-sparing agent for corticosteroid-dependent Crohn&rsquo;s disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn&rsquo;s disease; maintenance treatment in acute promyelocytic leukemia (APL); treatment component for non Hodgkin lymphoma (NHL), treatment of autoimmune hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mercaptopurine may be confused with methotrexate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Purinethol&reg; may be confused with propylthiouracil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with sixfold overdosages.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drug fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hyperpigmentation, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, intestinal ulcers, mucositis/oral lesions (rare), nausea (minimal), pancreatitis, sprue-like symptoms, stomach pain, vomiting (minimal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Oligospermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset 7-10 days; nadir 14 days; recovery: 21 days); anemia, bleeding, granulocytopenia, leukopenia, marrow hypoplasia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, ascites, biliary stasis, hepatic damage/injury, hepatic encephalopathy, hepatic necrosis, hepatomegaly, intrahepatic cholestasis, jaundice, parenchymal cell necrosis, toxic hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hyperuricosuria, renal toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hepatosplenic T cell lymphoma, immunosuppression, infection, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mercaptopurine or any component of the formulation; patients whose disease showed prior resistance to mercaptopurine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-related leukopenia, thrombocytopenia, and anemia are common; however, may be indicative of disease progression. Hematologic toxicity may be delayed. Bone marrow may appear hypoplastic (could also appear normal). Monitor for bleeding (due to thrombocytopenia) or infection (due to neutropenia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity has been reported, including jaundice, ascites, hepatic necrosis (may be fatal), intrahepatic cholestasis, parenchymal cell necrosis, and/or hepatic encephalopathy; may be due to direct hepatic cell damage or hypersensitivity. While hepatotoxicity or hepatic injury may occur at any dose, dosages &gt;2.5 mg/kg/day are associated with a higher incidence. Signs of jaundice generally appear early in treatment, after ~1-2 months (range: 1 week to 8 years) and may resolve following discontinuation; recurrence with rechallenge has been noted. Monitor liver function tests (monitor more frequently if used in combination with other hepatotoxic drugs or in patients with pre-existing hepatic impairment). Consider a reduced dose in patients with hepatic impairment. Withhold treatment for clinical signs of jaundice (hepatomegaly, anorexia, tenderness), deterioration in liver function tests, toxic hepatitis, or biliary stasis until hepatotoxicity is ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Mercaptopurine is immunosuppressive; the risk for infection is increased. Common signs of infection, such as fever and leukocytosis may not occur; lethargy and confusion may be more prominent signs of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy: Immunosuppressive agents, including mercaptopurine, are associated with the development of lymphoma and other malignancies. In an analysis of T-cell lymphomas associated with TNF blockers (with or without thiopurines) for the treatment of rheumatoid arthritis, Crohn&rsquo;s disease, ulcerative colitis, or ankylosing spondylitis (unlabeled uses for thiopurines), an increase in the incidence of T-cell lymphomas, most commonly mycosis fungoides/S&eacute;zary syndrome and hepatosplenic T-cell lymphoma (HSTCL) was reported  (Deepak, 2013). HSTCL is a rare white blood cell cancer that is usually fatal. Most HSTCL cases occurred in patients treated with a combination of TNF blockers and thiopurines, although cases of HSTCL also occurred in patients receiving azathioprine or mercaptopurine monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Consider dosage modification in patients with renal impairment. Some renal adverse effects may be minimized with hydration and prophylactic antihyperuricemic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thiopurine methyltransferase deficiency: Patients with homozygous genetic defect of thiopurine methyltransferase (TPMT) are more sensitive to myelosuppressive effects; generally associated with rapid myelosuppression. Significant mercaptopurine dose reductions will be necessary (possibly with continued concomitant chemotherapy at normal doses). Patients who are heterozygous for TPMT defects will have intermediate activity; may have increased toxicity (primarily myelosuppression) although will generally tolerate normal mercaptopurine doses. Consider TPMT testing for severe toxicities/excessive myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Azathioprine: Because azathioprine is metabolized to mercaptopurine, concomitant use with azathioprine may result in profound myelosuppression and should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; TPMT or xanthine oxidase inhibitors: Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be sensitive to myelosuppressive effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Error-prone terms: To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with sixfold overdosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: Immune response to vaccines may be diminished.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May decrease the metabolism of Mercaptopurine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase the serum concentration of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfamethoxazole: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Mercaptopurine may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Mercaptopurine may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13842767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Absorption is variable with food. Management: Take on an empty stomach at the same time each day 1 hour before or 2 hours after a meal. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13361082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been noted with second and third trimester use. Women of child bearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13361083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mercaptopurine is the active metabolite of azathioprine. Following administration of azathioprine, mercaptopurine can be detected in breast milk (Gardiner, 2006). It is not known if/how much mercaptopurine is found in breast milk following oral administration. According to the manufacturer, the decision to discontinue mercaptopurine or discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F193215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be administered with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F193214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mercaptopurine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (250): $1022.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Purinethol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $518.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (weekly initially, although clinical status may require increased frequency), bone marrow exam (to evaluate marrow status), liver function tests (weekly initially, then monthly; monitor more frequently if on concomitant hepatotoxic agents), renal function, urinalysis; consider TPMT genotyping to identify TPMT defect (if severe toxicity occurs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For use as immunomodulatory therapy in CD or UC, monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1-2 months throughout the course of therapy. LFTs should be assessed every 3 months. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Capmerin (PH);",
"     </li>",
"     <li>",
"      Empurine (PH, TH);",
"     </li>",
"     <li>",
"      Mercaptopurina Wellcome (ES);",
"     </li>",
"     <li>",
"      Merkaptopurin (TW);",
"     </li>",
"     <li>",
"      Merpurin (PH);",
"     </li>",
"     <li>",
"      Puri-Nethol (AE, AT, BE, BF, BG, BH, BJ, BR, CH, CI, CY, CZ, DE, EE, EG, ET, FI, GB, GH, GM, GN, HK, HR, ID, IE, IL, IN, IQ, IR, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NO, NZ, OM, PY, QA, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Purinethol (AR, AU, CN, FR, GR, IT, MX, NL, PH, PL, RU);",
"     </li>",
"     <li>",
"      Purinetone (PK, SG);",
"     </li>",
"     <li>",
"      Varimer (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Purine antagonist which inhibits DNA and RNA synthesis; acts as false metabolite and is incorporated into DNA and RNA, eventually inhibiting their synthesis; specific for the S phase of the cell cycle",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable and incomplete (~50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &gt; total body water; CNS penetration is poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~19%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and in GI mucosa; hepatically via xanthine oxidase and methylation via TPMT to sulfate conjugates, 6-thiouric acid, and other inactive compounds; first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (age dependent): Children: 21 minutes; Adults: 47 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (46% as mercaptopurine and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 173.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carter MJ, Lobo AJ and Travis SP, &ldquo;Guidelines for the Management of Inflammatory Bowel Disease in Adults,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 2004, 53(Suppl 5):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/15306569/pubmed\" id=\"15306569\" target=\"_blank\">",
"        15306569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danese M and Fiocchi C, &ldquo;Ulcerative Colitis,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2011, 365(18):1713-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/22047562/pubmed\" id=\"22047562\" target=\"_blank\">",
"        22047562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deepak P, Sifuentes H, Sherid M, et al, &ldquo;T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-&alpha;) Inhibitors: Results of the REFURBISH Study,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2013, 108(1):99-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/23032984/pubmed\" id=\"23032984\" target=\"_blank\">",
"        23032984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardiner SJ, Gearry RB, Roberts RL, et al, &ldquo;Exposure to Thiopurine Drugs Through Breast Milk is Low Based on Metabolite Concentrations in Mother-Infant Pairs,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2006, 62(4):453-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/16995866/pubmed\" id=\"16995866\" target=\"_blank\">",
"        16995866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gremse DA and Crissinger KD, &ldquo;Ulcerative Colitis in Children: Medical Management,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):807-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/12431133/pubmed\" id=\"12431133\" target=\"_blank\">",
"        12431133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(3): 547-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/10653870 /pubmed\" id=\"10653870 \" target=\"_blank\">",
"        10653870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/7718875 /pubmed\" id=\"7718875 \" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Linker CA, et al, \"A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 92(5):1556-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/9716583/pubmed\" id=\"9716583\" target=\"_blank\">",
"        9716583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Abreu MT, Cohen R, et al, &ldquo;American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      ,  2006, 130(3):935-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/16530531/pubmed\" id=\"16530531\" target=\"_blank\">",
"        16530531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lobel EZ, Korelitz BI, Xuereb MA, et al, &ldquo;A Search for the Optimal Duration of Treatment With 6-Mercaptopurine for Ulcerative Colitis,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2004, 99(3):462-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/15056086/pubmed\" id=\"15056086\" target=\"_blank\">",
"        15056086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manns MP, Czaja AJ, Gorham JD, et al, &ldquo;Diagnosis and Management of Autoimmune Hepatitis,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2010, 51(6):2193-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/20513004/pubmed\" id=\"20513004\" target=\"_blank\">",
"        20513004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markowitz J, Grancher K, Kohn N, et al, &ldquo;A Multicenter Trial of 6-Mercaptopurine and Prednisone in Children With Newly Diagnosed Crohn's Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000, 119(4):895-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/11040176/pubmed\" id=\"11040176\" target=\"_blank\">",
"        11040176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mosesso P and Palitti F, \"The Genetic Toxicology of 6-Mercaptopurine,\"",
"      <i>",
"       Mutat Res",
"      </i>",
"      , 1993, 296(3):279-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/7680107/pubmed\" id=\"7680107\" target=\"_blank\">",
"        7680107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, &ldquo;A Review of Immune Modifier Therapy for Inflammatory Bowel Disease: Azathioprine, 6-mercaptopurine, Cyclosporine, and Methotrexate,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1996, 91(3):423-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/8633486/pubmed\" id=\"8633486\" target=\"_blank\">",
"        8633486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmiegelow K, Glomstein A, Kristinsson J, et al, &ldquo;Impact of Morning versus Evening Schedule for Oral Methotrexate and 6-Mercaptopurine on Relapse Risk for Children With Acute Lymphoblastic Leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO),&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1997, 19(2):102-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/9149738/pubmed\" id=\"9149738\" target=\"_blank\">",
"        9149738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siegel CA and Sands BE, &ldquo;Review Article: Practical Management of Inflammatory Bowel Disease Patients Taking Immunomodulators,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2005, 22(1):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/15963074/pubmed\" id=\"15963074\" target=\"_blank\">",
"        15963074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stock W, La M, Sanford B, et al, &ldquo;What Determines the Outcomes for Adolescents and Young Adults With Acute Lymphoblastic Leukemia Treated on Cooperative Group Protocols? A Comparison of Children's Cancer Group and Cancer and Leukemia Group B Studies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(5):1646-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/18502832/pubmed\" id=\"18502832\" target=\"_blank\">",
"        18502832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas DA, O'Brien S, Cortes J, et al, &ldquo;Outcome With the Hyper-CVAD Regimens in Lymphoblastic Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(6):1624-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/15178574 /pubmed\" id=\"15178574 \" target=\"_blank\">",
"        15178574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimm S, Ettinger LJ, Holcenberg JS, et al, &ldquo;Phase I and Clinical Pharmacological Study of Mercaptopurine Administered as a Prolonged Intravenous Infusion,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1988, 45(4):1869-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/43/37559/abstract-text/4038917/pubmed\" id=\"4038917\" target=\"_blank\">",
"        4038917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9612 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37559=[""].join("\n");
var outline_f36_43_37559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193270\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193232\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193253\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193233\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193234\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193235\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193204\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193188\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878121\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193207\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3031909\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193268\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193212\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193192\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299673\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193197\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842767\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193199\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361082\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193241\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361083\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193215\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193214\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193201\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193216\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193191\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193211\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/4/30789?source=related_link\">",
"      Mercaptopurine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=related_link\">",
"      Mercaptopurine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_43_37560="Pathology of granuloma annulare - early lesion";
var content_f36_43_37560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathology of granuloma annulare - early lesion (H&amp;E 100x)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low power view shows two areas of incomplete collagen degeneration in the left lower and left upper areas of this photomicrograph with broad areas of normal intervening dermal collagen (interstitial or incomplete granuloma annulare). Early lesions of this type fail to show central areas of acellular necrobiotic collagen (H&amp;E 100x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37560=[""].join("\n");
var outline_f36_43_37560=null;
var title_f36_43_37561="Ductal carcinoma in situ: Treatment and prognosis";
var content_f36_43_37561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ductal carcinoma in situ: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Laura C Collins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Christine Laronga, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Julia S Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37561/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/43/37561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H562651833\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules. The diagnosis of DCIS has increased dramatically with the introduction of screening mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of therapy for DCIS is to prevent the development of invasive breast cancer. Therapeutic approaches include surgery, radiation therapy, and adjuvant endocrine therapy.",
"   </p>",
"   <p>",
"    The treatment of DCIS will be reviewed here. The pathology, epidemiology, diagnosis, and prognosis of DCIS and microinvasive carcinoma of the breast are presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=see_link\">",
"       \"Pathology of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=see_link\">",
"       \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=see_link\">",
"       \"Microinvasive breast carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651840\">",
"    <span class=\"h1\">",
"     LOCAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal carcinoma in situ (DCIS) of the breast represents a broad biologic spectrum of disease. The best form of local therapy is debated. Although mastectomy achieves excellent long-term survival with a local recurrence rate of less than 1 percent, it provides overly aggressive treatment for many women. On the other hand, breast conserving therapy (BCT) has less morbidity but is associated with a higher risk of local recurrence.",
"   </p>",
"   <p>",
"    Patients found to have invasive or microinvasive disease at surgery should be managed accordingly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10521717\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651847\">",
"    <span class=\"h3\">",
"     Mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastectomy is curative for over 98 percent of patients with DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Disease recurrence is rare after mastectomy (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Postmastectomy recurrences may be the result of unrecognized invasive carcinoma, inadequate margins or incomplete removal of breast tissue at the time of mastectomy.",
"   </p>",
"   <p>",
"    Although mastectomy as treatment for DCIS is highly effective in reducing new or recurrent breast cancers, it is more aggressive than is required for most women because survival is comparable with breast conserving surgery.",
"   </p>",
"   <p>",
"    Women treated with mastectomy are candidates for breast reconstruction; immediate reconstruction is usually preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link\">",
"     \"Breast reconstruction in women with breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with unilateral DCIS are at a modestly increased risk of developing either invasive breast cancer or DCIS in the contralateral breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Therefore, some women with DCIS choose contralateral prophylactic mastectomy to prevent a future breast cancer in the contralateral breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/9\">",
"     9",
"    </a>",
"    ], despite a lack of enthusiasm for this approach among many clinicians given the absence of a proven survival benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562652034\">",
"    <span class=\"h3\">",
"     Breast conserving therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast conserving therapy (BCT) refers to wide excision of the tumor with negative surgical margins followed by radiation therapy (RT) to eradicate any residual disease. The importance of RT in BCT is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H562651883\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Wide excision is also referred to as lumpectomy, partial mastectomy or breast conserving surgery. Studies comparing",
"    <strong>",
"    </strong>",
"    BCT with mastectomy for DCIS have demonstrated equivalent long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/7,11-14\">",
"     7,11-14",
"    </a>",
"    ]. However, local recurrence rates are higher with BCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of women with DCIS are candidates for BCT, as long as the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lesion should be limited to one quadrant or section of the breast, and may be either continuous or multiple smaller separate foci. This size criterion is relative and depends upon breast size (ratio of the size of the area of presumed DCIS to the overall size of the breast) and whether a cosmetically acceptable excision is possible.",
"     </li>",
"     <li>",
"      Achievement of histologically negative margins, as defined by tumor-filled ducts separated by a measurable distance from the inked surface. For women with DCIS, we suggest excision to a wide negative margin, ideally 10 mm if achievable. However, for women who will be treated with post-operative RT, a lesser margin is adequate (ie, 2 mm). We recognize it may not be possible to obtain margin widths of 10 mm, particularly with DCIS close to the skin or muscle. If the area of concern is close to the fascia, the dissection should be carried down to and include the pectoral fascia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H562651869\">",
"       'Margin width'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H530735136\">",
"       'Prognostic factors'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multifocal disease is not necessarily a contraindication to BCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/19\">",
"     19",
"    </a>",
"    ]. However, extensive disease that cannot be encompassed within a cosmetically acceptable resection or multi-centric disease is a contraindication to BCT. Mastectomy is indicated in this setting.",
"   </p>",
"   <p>",
"    Following BCT, post-excision mammography should be performed prior to the initiation of RT. This allows confirmation of complete excision of all suspicious calcification, which is of particular importance if they were extensively seen on the preoperative mammogram, approach the edge of the surgical specimen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the surgical margins are positive. Post-excision mammography showing residual suspicious calcifications indicates the need for further resection despite &ldquo;negative&rdquo; histologic margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Mammographic features of breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651862\">",
"    <span class=\"h3\">",
"     Pathologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with DCIS, complete tissue processing is essential to exclude small foci of invasive carcinoma, determine the size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of DCIS, ascertain the presence of contiguous or multifocal distribution, and evaluate the distance to the resection margins (margin width) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Consensus conferences have recommended that the pathology report should include nuclear grade (ie, low, intermediate, or high), the size or extent of the lesion (from direct measurements",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reconstruction), and the distance to the closest margin, including whether the margins were only focally or extensively involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Specimen orientation by the surgeon is necessary to identify specific margins and allow for targeted re-excision if necessary. The pathology of DCIS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most institutions routinely test DCIS for estrogen receptor (ER) and progesterone receptor (PR) because these results guide systemic therapy decisions (see",
"    <a class=\"local\" href=\"#H562652190\">",
"     'Systemic treatment'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of HER2 expression in DCIS is evolving. However, at present, consensus guidelines do not recommend routine testing of pure DCIS for HER2 overexpression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H3#H3\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Clinical utility of HER2 testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651869\">",
"    <span class=\"h4\">",
"     Margin width",
"    </span>",
"    &nbsp;&mdash;&nbsp;The margin width (distance between the edge of the DCIS and the closest inked margin) reflects the completeness of excision and is an important determinant of local recurrence in DCIS, particularly for patients considering breast conserving surgery in the absence of radiotherapy. The",
"    <span class=\"nowrap\">",
"     volume/extent",
"    </span>",
"    of DCIS, its distribution throughout a specimen, the volume of the excision, and the volume of DCIS deemed close to the margin (focal or extensive) may impact determinations of what constitutes a sufficient margin. The impact of margin width on prognosis for patients with DCIS is discussed below. (See",
"    <a class=\"local\" href=\"#H18124317\">",
"     'Prognosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H562651883\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When the surgeon is aware that a focus of microcalcifications represents DCIS on the basis of a core biopsy, complete resection of DCIS can be better achieved by bracketing the area of microcalcifications under mammographic guidance. For suspicious microcalcifications, this diagnostic strategy (definitive diagnosis by stereotactic vacuum-assisted biopsy followed by an image-guided resection of the bracketed area) maximizes the likelihood of a complete excision with adequate margins on the first attempt, thereby diminishing the need for re-excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. For patients in whom DCIS is associated with calcifications and the adequacy of the margins is in question, a post-excision mammogram can be helpful in guiding plans for re-excision. Residual suspicious calcifications warrant a wire-localized approach to re-excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651876\">",
"    <span class=\"h3\">",
"     Sentinel lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with DCIS do not require sentinel lymph node biopsy (SLNB) for assessment of the axillary nodes. However, women with DCIS are candidates for SLNB if they have microinvasive disease or are undergoing mastectomy because the performance of SLNB will be impossible at a later time if invasive disease is found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=see_link&amp;anchor=H564860029#H564860029\">",
"     \"Microinvasive breast carcinoma\", section on 'Management of the axilla'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of SLNB in DCIS is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=see_link&amp;anchor=H100034640#H100034640\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\", section on 'Role of sentinel node excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651883\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) after wide excision reduces the risk of local invasive and noninvasive recurrences. As described below, four randomized trials show that adjuvant RT significantly reduces the risk of in-breast tumor recurrence by 50 percent or greater compared to excision alone. However, treating all women who undergo wide excision for DCIS with adjuvant RT may be overtreatment for some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The majority of cases of DCIS do not recur when treated with excision alone and there may be subgroups of patients with DCIS in whom the risk of local recurrence is so low that RT may be of no benefit. The difficulty, however, is in reliably predicting those patients who would not recur in the absence of RT.",
"   </p>",
"   <p>",
"    The benefit of RT for DCIS was shown in a 2009 meta-analysis of RT compared to no further treatment following excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/35\">",
"     35",
"    </a>",
"    ]. Compared to excision alone, RT resulted in a reduction in the risk of all ipsilateral breast events (pooled hazard ratio [HR] 0.49; 95% CI 0.41-0.58). This translated into a number needed to treat of nine women to prevent one ipsilateral breast recurrence.",
"   </p>",
"   <p>",
"    In addition, the reduction in the risk of a local recurrence of RT appears to be long lasting, though this is not associated with a survival advantage. This was shown in a report of the long-term follow-up of the National Surgical Breast and Bowel Project Trial B-17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/14\">",
"     14",
"    </a>",
"    ]. At 15 years, compared to excision alone, RT resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower rate of ipsilateral invasive recurrence (8.9 versus 19.4 percent)",
"     </li>",
"     <li>",
"      Similar overall survival (83 versus 84 percent) and cumulative all-cause mortality rate through 15 years (HR for death 1.08, 95% CI 0.79-1.48, 17.1 versus 15.8 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10522284\">",
"    <span class=\"h3\">",
"     RT schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the treatment of invasive breast cancer, the standard of care for patients who wish for breast conservation is to deliver whole breast RT, following wide excision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, alternative approaches, such as the use of rapid fractionation schedules or accelerated partial breast RT are under investigation and early results are promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was demonstrated in two single institution trials that enrolled a total of 145 women who had undergone breast conserving surgery for DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/37\">",
"     37",
"    </a>",
"    ]. All patients received accelerated partial breast RT (41 to 42 Gy delivered over 15 fractions). In a combined analysis, the recurrence rate at five years was 4 percent, which was similar to the rate of recurrence following whole breast RT reported in the NSABP B-17 trial (range, 3 to 8 percent for noninvasive and invasive recurrences, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/38\">",
"     38",
"    </a>",
"    ]. Further evaluation of these techniques is required before they can be considered an alternative to whole breast RT for DCIS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/27/12728?source=see_link\">",
"     \"Accelerated partial breast irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link&amp;anchor=H759493#H759493\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'Shorter fractionation schedules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651897\">",
"    <span class=\"h3\">",
"     Omission of radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results from the clinical trials described above have been used to argue for RT in all women who undergo wide excision for pure DCIS. Some have argued that methodologic issues such as suboptimal pathologic evaluation and uncertainty about the completeness of wide excision in these trials may have led to an overestimation of the benefit of RT following wide excision. RT is expensive, time consuming, and may be accompanied by significant side effects. While it would be beneficial to distinguish between subgroups of patients with DCIS for whom RT is necessary versus those for whom RT offers little benefit, data from the above studies do not permit this distinction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61428491\">",
"    <span class=\"h4\">",
"     ECOG 5194",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Eastern Cooperative Oncology Group (ECOG) 5194 (E5194) observational study investigated excision without radiation therapy (RT) in women with DCIS; the extent of the DCIS for eligibility was &lt;2.5 cm in low to intermediate grade DCIS and &lt;1.0 cm for high grade DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/39\">",
"     39",
"    </a>",
"    ]. In this trial, margins of at least 3 mm were required (after detailed pathologic assessment involving sequential sectioning and embedding of the complete specimen), and a negative post-excision mammogram was obtained for all participants.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    following excision was allowed but not mandated. With a median follow-up of 6.7 years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The local recurrence rate (LRR) at five-years for patients with low- or intermediate-grade DCIS (n = 565) was 6.1 percent (95% CI 4.1-8.2).",
"     </li>",
"     <li>",
"      The LRR at five-years for patients with high-grade DCIS (n = 105) was 15.3 percent (95% CI 8.2-22.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that local excision alone may be sufficient for select patients with low- to intermediate-grade DCIS, but it is inadequate for patients with high grade lesions. Therefore, RT remains an important treatment for reducing risk of ipsilateral breast disease, and the results from ECOG 5194 suggest that patients may benefit from RT.",
"   </p>",
"   <p>",
"    Identifying patients who can safely be managed with surgical excision using clinicopathologic data remains a challenge, and some patients may value the reduction in all recurrence (DCIS and invasive) enough to warrant pursuing post-excision RT. &nbsp;At present it remains apparent that the selection of patients for excision alone is not straightforward, and not easily defined by standard variables such as margins, size, age, or grade. Early preliminary results suggest that gene expression analysis may help to select such patients. (See",
"    <a class=\"local\" href=\"#H32154110\">",
"     'Gene expression analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32154110\">",
"    <span class=\"h4\">",
"     Gene expression analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive study, there are no clinicopathologic features of DCIS that reliably predict a low enough rate of local recurrence with wide excision alone that radiation therapy (RT) would not further reduce risk of local failure.",
"   </p>",
"   <p>",
"    A DCIS Recurrence Score utilizing a multigene assay has been developed and a prospective evaluation of this assay was performed using tumors from 327 patients who participated in the aforementioned E5194 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/40\">",
"     40",
"    </a>",
"    ]. In a preliminary analysis, patients were stratified by recurrence score into three groups that were associated the following risks of an ipsilateral breast event (DCIS or invasive breast cancer) or invasive breast cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low (&lt; 39) &ndash; 12 and 5 percent, respectively",
"     </li>",
"     <li>",
"      Intermediate (39-54) &ndash; 25 and 9 percent, respectively",
"     </li>",
"     <li>",
"      High (&ge;55) &ndash; 27 and 19 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that the DCIS score may help select patients who should undergo adjuvant radiation. However, further validation of these results is required before the multigene assay can become a part of clinical practice. It is also worth noting that a 12 percent risk of an ipsilateral breast event at 10 years in the lowest risk category may not be low enough to justify the routine omission of post-excision RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562652190\">",
"    <span class=\"h1\">",
"     SYSTEMIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary role of systemic treatment is to reduce the risk of invasive breast cancer in the ipsilateral or contralateral breast. The risk of distant metastases in women with DCIS is exceedingly low and overall prognosis is excellent and as such, chemotherapy plays no role in the management of these patients. Approximately 50 to 75 percent of DCIS lesions express estrogen receptors (ER)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone receptors (PR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Of the endocrine agents approved for use as adjuvant therapy for invasive breast cancer, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is approved in the United States to prevent invasive breast cancer recurrences in women with DCIS. For women with ER-positive DCIS who have not undergone a bilateral mastectomy, we suggest tamoxifen rather than observation. This preference is based upon an improvement in recurrence rates without a proven survival benefit. The data to support this recommendation are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641529608\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is more effective than placebo in reducing the risk of recurrence of both in situ or invasive carcinoma, although there is no apparent benefit in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/14,44-46\">",
"     14,44-46",
"    </a>",
"    ]. This was shown in a 2012 meta-analysis of tamoxifen following surgery with or without radiation therapy (RT) for DCIS, which reported the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      to surgery and RT for DCIS significantly reduced the recurrence risk of ipsilateral DCIS (hazard ratio [HR] 0.75, 95% CI 0.61-0.92) and contralateral DCIS (relative risk [RR] 0.50, 95% CI 0.28-0.87).",
"     </li>",
"     <li>",
"      There was trend towards a lower risk of ipsilateral invasive carcinoma (HR 0.79, 95% CI 0.61-1.01) and a lower risk for contralateral invasive carcinoma (RR 0.57, 95% CI 0.39-0.83).",
"     </li>",
"     <li>",
"      There was no benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in all cause mortality (RR 1.11, 95% CI 0.89-1.39).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641529634\">",
"    <span class=\"h3\">",
"     Should you test DCIS for ER status?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in women with DCIS, it appears that those with ER-positive disease are most likely to benefit from treatment. Therefore we suggest testing DCIS for ER status to help inform treatment decisions.",
"   </p>",
"   <p>",
"    The ability of ER-status to predict response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for women with DCIS was addressed in a retrospective analysis of 732 women (40 percent) who participated on the National Surgical Breast and Bowel Project 24 (NSABP B-24), a randomized trial of five years of tamoxifen or placebo after local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/48\">",
"     48",
"    </a>",
"    ]. ER and PR were positive in 76 and 66 percent of patients, respectively. Compared to placebo, tamoxifen for five years was associated with the following results at 10 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among women with ER-positive disease (n = 556) &ndash; a significant reduction in any breast cancer event (HR 0.58, 95% CI 0.42-0.81)",
"     </li>",
"     <li>",
"      Among women with ER-negative disease (n = 176) &ndash; a trend towards a reduction in any breast cancer event (HR 0.88, 95% CI 0.49-1.59)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In multivariate analysis, only two factors were independently associated with a significant reduction in any breast cancer event: treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (HR 0.64, 95% CI 0.48-0.86) and age &lt;50 years at entry (HR 0.62, 95% CI 0.51-0.76). Although a trend towards a reduction in breast cancer events was seen in the ER-negative cohort, this may be due to a high false-negative rate in ER-testing at the institutional level. Support for this comes from a sample of 102 cases that underwent both institutional and central hormone receptor testing by immunohistochemistry. Agreement between central and institutional testing for ER was only 75 percent.",
"   </p>",
"   <p>",
"    These results suggest that patients with ER-positive DCIS benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . For patients with ER-negative DCIS, the benefit of tamoxifen is less clear. In the absence of prospective data, we agree with recommendations from the National Comprehensive Cancer Network (NCCN) Task Force and favor testing for ER in pure DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/49\">",
"     49",
"    </a>",
"    ]. We suggest tamoxifen for women with ER-positive DCIS. However, the decision to administer tamoxifen for women with ER-negative DCIS requires an individualized discussion on the risks and benefits of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641529642\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no data on the use of aromatase inhibitors in patients with DCIS. Although the breast cancer prevention study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    versus placebo was open to women with DCIS treated by mastectomy as part of their high-risk population, they only constituted 2.5 percent of the study population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/50\">",
"     50",
"    </a>",
"    ]. Clinical trials of anastrazole are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641529649\">",
"    <span class=\"h2\">",
"     HER2-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to invasive breast cancer, DCIS more often expresses human epidermal growth factor receptor 2 (HER2). As an example, in a study of 708 malignant ductal lesions (59 with DCIS, 649 with invasive disease), the proportion that were HER2 positive was 56 and 15 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00769379\">",
"     The National Surgical Breast and Bowel Project B-43 (NSABP B-43) study",
"    </a>",
"    is currently evaluating the effect of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to radiation therapy for women who underwent a lumpectomy for DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18124317\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735830\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective and prospective analyses report an equivalent long-term survival regardless of local treatment (ie, mastectomy, breast conserving management) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. Data from the Surveillance, Epidemiology, and End Results (SEER) - Medicare data set on 8466 cases of DCIS showed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival for women aged 67 years or older is similar to women not diagnosed with breast cancer.",
"     </li>",
"     <li>",
"      Women aged 67 years or older are more likely to die of cardiovascular disease than breast cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among women diagnosed with DCIS, the risk of death from breast cancer is estimated at 1.9 percent within ten years based on the Surveillance, Epidemiology, and End Results (SEER) data for women diagnosed from 1984 to 1989 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/57\">",
"     57",
"    </a>",
"    ]. Nearly all patients with a noninvasive recurrence and the majority of those with an invasive recurrence survive their disease after subsequent treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735837\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women treated with a total mastectomy have a 1 percent risk of ipsilateral recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/58\">",
"     58",
"    </a>",
"    ]. Among women treated with breast conserving therapy, women treated with adjuvant radiation therapy (RT) have a lower incidence of ipsilateral events than those treated with surgery alone (16 versus 32 percent, respectively, at 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/58\">",
"     58",
"    </a>",
"    ]. Approximately one-half of all local-regional recurrences are invasive, regardless of treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/7,11,59-64\">",
"     7,11,59-64",
"    </a>",
"    ]. The most important cause of a local recurrence appears to be inadequate excision (histologically positive margins). (See",
"    <a class=\"local\" href=\"#H530735188\">",
"     'Margin width'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735136\">",
"    <span class=\"h3\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and histopathologic factors that may predict risk of recurrence include patient age, nuclear grade, presence of comedo-type necrosis, tumor size, and margin width.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735181\">",
"    <span class=\"h4\">",
"     Grade and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade lesions, particularly those of the &ldquo;comedo subtype&rdquo;, are more likely to recur locally in the short term than are low grade lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Invasive cancer that develops after treatment of high grade DCIS is more likely to be poorly differentiated and associated with worse prognosis than one that develops after treatment of low grade DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/65,69\">",
"     65,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=see_link&amp;anchor=H1220079795#H1220079795\">",
"     \"Pathology of breast cancer\", section on 'Ductal carcinoma in situ'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735188\">",
"    <span class=\"h4\">",
"     Margin width",
"    </span>",
"    &nbsp;&mdash;&nbsp;The margin width is defined as the distance between the boundary of the DCIS and the closest inked margin. It reflects the completeness of excision and is an important determinant of local recurrence in DCIS, particularly in the absence of radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/16\">",
"     16",
"    </a>",
"    ]. Following breast conserving therapy, the vast majority of local recurrences are near the site of the original tumor and rarely in a different quadrant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H562651869\">",
"     'Margin width'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The relationship between margin width and in-breast tumor recurrence was demonstrated in a 2012 meta-analysis of 21 studies (n = 7564 patients) with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative surgical margins on excision were significantly associated with a lower risk of in-breast tumor recurrence compared to positive margins among those who underwent adjuvant RT (odds ratio [OR] 0.46, 95% CI 0.35-0.59) and those who did not undergo RT (OR 0.34, 95% CI 0.24-0.47).",
"     </li>",
"     <li>",
"      A wider negative margin (&gt;10 mm) was associated with a significant reduction in the in-breast tumor recurrence risk compared to a more narrow margin &lt;2 mm (OR 0.46, 95% CI 0.29-0.69).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the results of the meta-analysis support a wide margin at excision of DCIS, only 5 of the 21 studies in the meta-analysis reported margins &gt;10 mm. In addition, only 3 and 9 percent of patients treated with or without RT, respectively, achieved a 10 mm margin.",
"   </p>",
"   <p>",
"    Furthermore, multiple factors that contribute to the risk of in-breast tumor recurrence (ie, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , nuclear grade, tumor size) were not accounted for in the meta-analysis. Despite these shortcomings, this meta-analysis supports the importance of excision to a negative surgical margin for women undergoing breast conserving therapy for DCIS. (See",
"    <a class=\"local\" href=\"#H562652034\">",
"     'Breast conserving therapy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530735698\">",
"    <span class=\"h4\">",
"     Van Nuys prognostic index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Van Nuys Prognostic Index (VNPI) and an updated version, the University of Southern California",
"    <span class=\"nowrap\">",
"     (USC)/VNPI,",
"    </span>",
"    combine four prognostic factors (size, margin width, age, and histologic classification) into a score that intends to predict the likelihood of local recurrence following wide excision alone in patients with DCIS (",
"    <a class=\"graphic graphic_table graphicRef62510 \" href=\"mobipreview.htm?26/27/27067\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/18,72\">",
"     18,72",
"    </a>",
"    ]. The pathologic classification defines three groups of patients by the presence or absence of high nuclear grade and comedo-type necrosis: (1) non-high-grade DCIS without comedo-type necrosis, (2) non-high-grade DCIS with comedo-type necrosis, and (3) high-grade DCIS with or without comedo-type necrosis. The pathologic classification score, in combination with scores (each 1 to 3) for margins, tumor size, and age are totaled to give an overall VNPI score ranging from 4 to 12. While the original analysis identified women at low risk for recurrence for whom radiation therapy was not required, attempts at replication and validation of the",
"    <span class=\"nowrap\">",
"     USC/VNPI",
"    </span>",
"    score in other datasets have had varying success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/6,16,73-75\">",
"     6,16,73-75",
"    </a>",
"    ]. Therefore, we do not use the VNPI in our practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651954\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of post-treatment surveillance after treatment for DCIS and early breast cancer are early recognition and treatment of potentially curable disease recurrences and second primary breast cancers, evaluation for therapy-related complications, and detection of symptoms consistent with metastatic disease. As with invasive disease, history and physical examination and routine mammography form the cornerstone of posttreatment surveillance (",
"    <a class=\"graphic graphic_table graphicRef61501 \" href=\"mobipreview.htm?5/39/5758\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530734871\">",
"    <span class=\"h1\">",
"     APPROACH TO RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of all local-regional recurrences are invasive, regardless of treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/11,63,64\">",
"     11,63,64",
"    </a>",
"    ]. In one study, the 15-year rate of any locoregional recurrence following treatment for DCIS was 19 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37561/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H530735837\">",
"     'Recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23918616\">",
"    <span class=\"h2\">",
"     Locoregional treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for a patient with recurrent DCIS is based upon disease extent, location, and the prior surgical approach (ie, mastectomy versus wide excision): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients treated with breast conserving therapy (ie, prior wide local excision plus RT), we would perform a mastectomy rather than breast conserving surgery because these patients are not candidates for further RT.",
"     </li>",
"     <li>",
"      For patients treated with breast conserving surgery and who did not undergo previous RT, options include repeat excision plus RT or mastectomy. A choice between them depends on the patient and provider preferences.",
"     </li>",
"     <li>",
"      Although rare, patients who underwent a mastectomy without RT may experience a recurrence in the mastectomy flap. For these patients, we perform excision of the area. These patients should also meet with a radiation oncologist to discuss the role of post-excision RT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link\">",
"       \"Management of locoregional recurrence of breast cancer after mastectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an invasive local recurrence after treatment for DCIS, we perform a metastatic work-up. The management of these patients is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of locoregional recurrence of breast cancer after breast conserving therapy\", section on 'Staging workup'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23918625\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with recurrent DCIS who were not prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    previously should be offered tamoxifen as chemoprevention. (See",
"    <a class=\"local\" href=\"#H641529608\">",
"     'Tamoxifen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who were on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and experienced a recurrence of pure DCIS, the benefit of continued tamoxifen following locoregional treatment for recurrent disease is not clear. These patients should meet with a medical oncologist (if one was not involved earlier in their care). While some experts prefer to discontinue tamoxifen in these patients, others may prefer to switch to a different endocrine therapy (especially in postmenopausal women) or to continue tamoxifen. In the absence of data to inform a preferred option, the role of endocrine therapy as chemoprevention (for women who experience a recurrence of DCIS while on tamoxifen) should be discussed with their physician.",
"   </p>",
"   <p>",
"    If the recurrence included any invasive disease, it should be treated in a manner appropriate for newly diagnosed invasive breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3492?source=see_link\">",
"       \"Patient information: Ductal carcinoma in situ (DCIS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H562651961\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules. The goal of therapy for DCIS is to prevent the development of invasive breast cancer. Therapeutic approaches include surgery, radiation therapy, and adjuvant endocrine therapy. (See",
"      <a class=\"local\" href=\"#H562651833\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Simple mastectomy achieves an excellent \"cure\" rate for DCIS, with a recurrence rate of approximately 1 percent. (See",
"      <a class=\"local\" href=\"#H562651847\">",
"       'Mastectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast conserving therapy (BCT) for DCIS includes wide excision followed by radiation therapy (RT) and results in breast cancer-specific survival rates comparable to mastectomy, although the rate of local recurrence is slightly higher with breast conservation. Patients with a lesion limited to one quadrant or section of the breast are candidates for BCT. The goal of wide excision should be to widely excise the entire focus of DCIS to achieve negative margins. Re-excision(s) or mastectomy should be performed if needed to obtain negative margins. (See",
"      <a class=\"local\" href=\"#H562652034\">",
"       'Breast conserving therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are candidates for breast conserving therapy, we recommend",
"      <strong>",
"      </strong>",
"      BCT over mastectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend that women undergoing breast conserving therapy receive RT in addition to wide excision (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H562652034\">",
"       'Breast conserving therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with very small foci of low grade DCIS, breast conserving surgery only (ie, omission of RT) with widely negative margins (ideally 10 mm) or a negative re-excision is an option. However, there is no prospective randomized evidence to support the omission of adjuvant radiation, even in selected low-risk cases. (See",
"      <a class=\"local\" href=\"#H562651883\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      For patients with ductal carcinoma in situ (DCIS) undergoing breast conserving surgery, we recommend not performing surgical evaluation of the axilla (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with microinvasion or extensive ductal carcinoma in situ undergoing a mastectomy, we suggest sentinel lymph node biopsy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link&amp;anchor=H20#H20\">",
"       \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Ductal carcinoma in situ'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with DCIS, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      rather than observation following breast conserving treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest testing for ER status in pure DCIS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women with ER-positive disease, we suggest tamoxifen treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the decision to administer tamoxifen for women with ER-negative DCIS requires an individualized discussion on the risks and benefits of treatment. (See",
"      <a class=\"local\" href=\"#H641529634\">",
"       'Should you test DCIS for ER status?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients diagnosed with DCIS have an excellent prognosis, whether treated with mastectomy or breast conserving therapy, and approximately one-half of all local-regional recurrences are invasive, regardless of treatment approach. (See",
"      <a class=\"local\" href=\"#H18124317\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for a patient diagnosed with a recurrence following original treatment for DCIS is based upon whether the disease is purely in situ or has an invasive component, the disease extent, location, prior surgical approach (ie, mastectomy versus wide excision), and whether RT was previously administered. (See",
"      <a class=\"local\" href=\"#H530734871\">",
"       'Approach to recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS). file://consensus.nih.gov/2009/dcis.htm (Accessed on April 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/2\">",
"      Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980; 192:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/3\">",
"      von Rueden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet 1984; 158:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/4\">",
"      Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 1985; 150:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/5\">",
"      Kinne DW, Petrek JA, Osborne MP, et al. Breast carcinoma in situ. Arch Surg 1989; 124:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/6\">",
"      Silverstein MJ. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 2003; 17:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/7\">",
"      Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001; 28:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/8\">",
"      Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003; 56:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/9\">",
"      Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009; 27:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/10\">",
"      Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr 2010; 2010:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/11\">",
"      Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005; 103:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/12\">",
"      Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 2005; 63:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/13\">",
"      Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002; 53:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/14\">",
"      Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/15\">",
"      Meijnen P, Oldenburg HS, Peterse JL, et al. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2008; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/16\">",
"      Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003; 90:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/17\">",
"      Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 340:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/18\">",
"      Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/19\">",
"      Rakovitch E, Pignol JP, Hanna W, et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol 2007; 25:5591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/20\">",
"      Gluck BS, Dershaw DD, Liberman L, Deutch BM. Microcalcifications on postoperative mammograms as an indicator of adequacy of tumor excision. Radiology 1993; 188:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/21\">",
"      Aref A, Youssef E, Washington T, et al. The value of postlumpectomy mammogram in the management of breast cancer patients presenting with suspiciouis microcalcifications. Cancer J Sci Am 2000; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/22\">",
"      Grann A, Abdou JC, Dragman N, Goodman R. The value of postexcision preradiation mammography in patients with early-stage breast cancer. Am J Clin Oncol 2004; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/23\">",
"      de Mascarel I, MacGrogan G, Mathoulin-P&eacute;lissier S, et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94:2134.",
"     </a>",
"    </li>",
"    <li>",
"     Lagios MD. Practical pathology of duct carcinoma in situ: How to derive optimal data from the pathologic examination. In: Ductal Carcinoma of the Breast, Silverstein MJ (Ed), Lippincott Williams and Wilkins, Philadelphia 2002. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/25\">",
"      Gilcrease MZ, Sahin AA. Detection of ductal carcinoma in situ by screening mammography: pathologic features important for clinical management. Breast Diseases: A Year Book Quarterly 2003; 13:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/26\">",
"      Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997; 80:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/27\">",
"      International Breast Cancer Consensus Conference. Image-detected breast cancer: state of the art diagnosis and treatment. International Breast Cancer Consensus Conference. J Am Coll Surg 2001; 193:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/28\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/29\">",
"      Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/30\">",
"      Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/31\">",
"      White RR, Halperin TJ, Olson JA Jr, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Ann Surg 2001; 233:769.",
"     </a>",
"    </li>",
"    <li>",
"     Silverstein MJ, Larsen L, Soni R, et al. Breast biopspy and oncoplastic surgery for the patient with ductal carcinoma in situ: Surgical, pathologic, and radiologic issues. In: Ductal Carcinoma in Situ of the Breast, Silverstein MJ (Ed), Lippincortt Williams and Wilkins, Philadelphia 2002. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/33\">",
"      Silverstein MJ, Lagios MD. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? No. One size does not fit all: an argument against the routine use of radiation therapy for all patients with ductal carcinoma in situ of the breast who elect breast conservation. J Surg Oncol 2007; 95:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/34\">",
"      Buchholz TA, Haffty BG, Harris JR. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol 2007; 95:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/35\">",
"      Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast 2009; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/36\">",
"      Shah C, McGee M, Wilkinson JB, et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer 2012; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/37\">",
"      Ciervide R, Dhage S, Guth A, et al. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83:e159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/38\">",
"      Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/39\">",
"      Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:5319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/40\">",
"      Solin LJ, Gray R, Baehner FL, Butler S. A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. CTRC-AACR San Antonio Breast Cancer Symposium 2011; Abstr S4-6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/41\">",
"      Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001; 70:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/42\">",
"      Selim AG, El-Ayat G, Wells CA. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 2002; 55:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/43\">",
"      Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 2006; 106:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/44\">",
"      Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/45\">",
"      Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/46\">",
"      Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/47\">",
"      Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012; 10:CD007847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/48\">",
"      Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 2012; 30:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/49\">",
"      Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw 2009; 7 Suppl 6:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/50\">",
"      Goss PE, Ingle JN, Al&eacute;s-Mart&iacute;nez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/51\">",
"      Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 2003; 9:495S.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00053898?term=NCT00053898&amp;rank=1 (Accessed on March 29, 2011).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00072462?term=IBIS+II&amp;rank=2 (Accessed on March 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/54\">",
"      Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23:974.",
"     </a>",
"    </li>",
"    <li>",
"     Radiation Therapy With or Without Trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. file://clinicaltrials.gov/ct2/show/NCT00769379 (Accessed on December 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/56\">",
"      Schonberg MA, Marcantonio ER, Ngo L, et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011; 29:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/57\">",
"      Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000; 160:953.",
"     </a>",
"    </li>",
"    <li>",
"     Silverstein M. Predicting local invasive recurrence after conservative treatment. 2007. appliedresearch.cancer.gov/dcis/workshop/dcis_silverstein.html (Accessed on April 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/59\">",
"      Rodrigues N, Carter D, Dillon D, et al. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/60\">",
"      Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998; 16:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/61\">",
"      Solin LJ, Fourquet A, Vicini FA, et al. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer 2005; 41:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/62\">",
"      Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg 2004; 188:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/63\">",
"      Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003; 95:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/64\">",
"      Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010; 2010:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/65\">",
"      Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/66\">",
"      Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995; 75:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/67\">",
"      Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993; 71:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/68\">",
"      Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999; 85:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/69\">",
"      Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/70\">",
"      Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 1992; 70:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/71\">",
"      Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 2012; 104:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/72\">",
"      Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/73\">",
"      MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 2007; 110:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/74\">",
"      Di Saverio S, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008; 109:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37561/abstract/75\">",
"      de Mascarel I, Bonichon F, MacGrogan G, et al. Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations. Breast Cancer Res Treat 2000; 61:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14220 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-018646983B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37561=[""].join("\n");
var outline_f36_43_37561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H562651961\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562651833\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562651840\">",
"      LOCAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10521717\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H562651847\">",
"      - Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H562652034\">",
"      - Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H562651862\">",
"      - Pathologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H562651869\">",
"      Margin width",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H562651876\">",
"      - Sentinel lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H562651883\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10522284\">",
"      - RT schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H562651897\">",
"      - Omission of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61428491\">",
"      ECOG 5194",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32154110\">",
"      Gene expression analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562652190\">",
"      SYSTEMIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641529608\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H641529634\">",
"      - Should you test DCIS for ER status?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641529642\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641529649\">",
"      HER2-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18124317\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530735830\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530735837\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H530735136\">",
"      - Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H530735181\">",
"      Grade and histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H530735188\">",
"      Margin width",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H530735698\">",
"      Van Nuys prognostic index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562651954\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H530734871\">",
"      APPROACH TO RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23918616\">",
"      Locoregional treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23918625\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562651961\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/27/27067\" title=\"table 1\">",
"      Van Nuys Prognostic Index DCIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/39/5758\" title=\"table 2\">",
"      Breast cancer surveillance guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/27/12728?source=related_link\">",
"      Accelerated partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3492?source=related_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_43_37562="Epidemiology and pathogenesis of systemic lupus erythematosus";
var content_f36_43_37562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Bevra H Hahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/43/37562/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/43/37562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of systemic lupus erythematosus (SLE) in the population is 20 to 150 cases per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In women, prevalence rates vary from 164 (white) to 406 (African American) per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/2\">",
"     2",
"    </a>",
"    ]. Due to improved detection of mild disease, the incidence nearly tripled in the last 40 years of the 20th century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/4\">",
"     4",
"    </a>",
"    ]. Estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Geographic and racial distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both geography and race affect the prevalence of SLE and of frequency and severity of clinical and laboratory manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disease appears to be more common in urban than rural areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prevalence of SLE is higher among Asians, Afro-Americans, Afro-Caribbeans, and Hispanic Americans compared with Americans of European decent in the United States, and among Asian Indians compared with Caucasians in Great Britain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/6,9,10\">",
"       6,9,10",
"      </a>",
"      ]. In comparison, SLE occurs infrequently in Blacks in Africa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In New Zealand, the prevalence and mortality of SLE are higher in Polynesians than in Caucasians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Photosensitivity and discoid skin lesions may be more frequent clinical manifestations in patients with Northern European than those with Southern European ancestry; the former group is, however, less likely to have anti-cardiolipin and anti-dsDNA antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Hormonal factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An estrogen effect is suggested by a number of observations including the female-to-male ratio of SLE in different age groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, in whom sex hormonal effects are presumably minimal, the female-to-male ratio is 3:1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, especially in women of child-bearing years, the ratio ranges from 7:1 to 15:1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/2,16\">",
"       2,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In \"older\" individuals, especially post-menopausal women, the ratio is approximately 8:1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In support of the potential role of estrogens in predisposing to SLE, the Nurse's Health study showed that women with early menarche, or treated with estrogen-containing regimens, such as oral contraceptives or postmenopausal hormone replacement therapies, have a significantly increased risk for SLE (hazard ratios of 1.5 to 2.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Factors related to the X chromosome may also be important in predisposing women to SLE. At least three predisposing genes are located on X chromosomes (IRAK1, MECP2, TLR7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/18\">",
"     18",
"    </a>",
"    ]. There is also evidence for a gene dose effect, since the prevalence of XXY (Klinefelter's syndrome) is increased 14-fold in men with SLE when compared with the general population of men, whereas XO (Turner's syndrome) is underrepresented in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possibilities for female predisposition include: X-inactivation, imprinting, X or Y chromosome genetic modulators, differential methylation of DNA and acetylation of histones bound to DNA, intrauterine influences, chronobiologic differences, pregnancy, and menstruation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixty-five percent of patients with SLE have disease onset between the ages of 16 and 55 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/22\">",
"     22",
"    </a>",
"    ]. Of the remaining cases, 20 percent present before age 16 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/23\">",
"     23",
"    </a>",
"    ], and 15 percent after age 55 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/24\">",
"     24",
"    </a>",
"    ]. Median ages at diagnosis for white females range from 37 to 50 years, in white males from 50 to 59, in black females from 15 to 44 and in black males from 45 to 64 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Factors affecting disease outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different epidemiologic subgroups (eg,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    gender, and age of onset) tend to have varying degrees of disease activity and may thus affect disease outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blacks and Mexican Hispanics in the United States have a poorer renal prognosis than Caucasians, a finding not entirely independent of socioeconomic status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/25\">",
"       25",
"      </a>",
"      ]. Blacks are more likely to have anti-Sm, anti-RNP, discoid skin lesions, proteinuria, psychosis, and serositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. Blacks with lupus nephritis are also less likely to respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      treatment than Whites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinical status is poorer in those with less education [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/25,29\">",
"       25,29",
"      </a>",
"      ]; this effect may reflect poor compliance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/30\">",
"       30",
"      </a>",
"      ]. Clinical status is also poorer in those with lower socioeconomic status and with inadequate access to medical care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The extent and degree of activity of SLE varies in different countries and in different ethnic groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Men with lupus tend to have higher frequencies of renal disease, skin manifestations, cytopenias, serositis, neurologic involvement, thrombosis, cardiovascular disease, hypertension, and vasculitis than women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/34\">",
"       34",
"      </a>",
"      ]. In contrast, Raynaud phenomenon, photosensitivity, and mucosal ulceration are less frequent manifestations in men than women. Most, but not all studies suggest that men have a higher one-year mortality rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/34-39\">",
"       34-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SLE in children tends to be symptomatically more severe than in adults, with a high incidence of malar rashes, nephritis, pericarditis, hepatosplenomegaly, and hematologic abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/23,35\">",
"       23,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lupus tends to be milder in the elderly, who often have a presentation more similar to that of drug-induced lupus. Clinical features of lupus in older patients include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/35,40-42\">",
"     35,40-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A lower ratio of affected women to men than for younger patients",
"     </li>",
"     <li>",
"      Lower incidence of malar rash, photosensitivity, purpura, alopecia, Raynaud phenomenon, renal, central nervous system, and hematologic involvement,",
"     </li>",
"     <li>",
"      Lower prevalence of anti-La, anti-Sm, and anti-RNP antibodies and of hypocomplementemia",
"     </li>",
"     <li>",
"      Greater prevalence of sicca symptoms, serositis, pulmonary involvement, and musculoskeletal manifestations",
"     </li>",
"     <li>",
"      Greater prevalence of rheumatoid factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of SLE remains unknown and is clearly multifactorial. Many observations suggest a role for genetic, hormonal, immunologic, and environmental factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations are compatible with a genetic role in the pathogenesis of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a high concordance rate (14 to 57 percent) of SLE in monozygotic twins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Five to 12 percent of relatives of patients with SLE have the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/48\">",
"       48",
"      </a>",
"      ], and there is an increased frequency of anti-C1q and anti-cardiolipin antibodies and C3 and C4 abnormalities in relatives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-seven percent of 195 children of mothers with lupus had a positive test for anti-nuclear antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genome-wide association studies (GWAS) have identified 30 to 40 gene loci with polymorphisms (or, rarely, mutations) that predispose to SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/18,51-53\">",
"     18,51-53",
"    </a>",
"    ]. The gene polymorphisms that increase risk for SLE can be understood best if SLE is considered to be caused initially by pathogenic autoantibodies and immune complexes (IC) that consist of nucleic acid derived from dead and dying cells and antibodies that bind to these nucleic acids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteins bound to them, and that production of those autoantibodies and IC depend upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of innate immunity - Important in such activation are interactions between toll-like receptor 7 (TLR7) and ribonucleic acid (RNA) and toll-like receptor 9 (TLR9) and deoxyribonucleic acid (DNA).",
"     </li>",
"     <li>",
"      Activation of adaptive immunity - T cells and B cells may be activated by interaction with self-antigens on or released by apoptotic cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic factors that confer the highest hazard ratios (HR) of 5 to 25 are deficiencies of the complement components C1q (required to clear apoptotic cells), C4A and B, C2, or the presence of a mutated TREX1 gene (encodes the three prime repair endonuclease1 enzyme that degrades DNA). Each of these is relatively rare in the population.",
"   </p>",
"   <p>",
"    The most common genetic predisposition is found at the major histocompatibility locus (MHC). The MHC contains genes for antigen presenting molecules (class I human leukocyte antigens [HLA-A, -B, and -C] and class II HLA molecules [HLA-DR, -DQ, and DP]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .) The MHC also contains genes for some complement components, cytokines, and heat shock protein.",
"   </p>",
"   <p>",
"    Predisposing loci, which include HLA-DR2 and HLA-DR3, are associated with HR of approximately 2, but the region is complex and involves multiple genes across the entire 120-gene region in multiple ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Within HLA-DRB1 loci, HLA-DRB1*0301 and HLA-DRB1*1501 predispose to SLE whereas HLA-DRB1*1401 reduces risk.",
"   </p>",
"   <p>",
"    Other genes with predisposing variants involve some associated with innate immunity (IRF5, Stat4, IRAK1, TNFAIP3, SPP1), most of which are associated with interferon alpha (IFNa) pathways. Overexpression of IFNa-induced genes is found in the peripheral blood cells of approximately 60 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/56\">",
"     56",
"    </a>",
"    ]. Some of the lupus-predisposing polymorphisms in STAT4, PTPN22 and IRF5 are associated with high levels of or increased sensitivity to IFN-a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Furthermore, STAT4 and IRF5 may have additive effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Still other predisposing genes involve lymphocyte signaling (PTPN22, OX40L, PD-1, BANK-1, LYN, BLK), each of which plays a role in activation or suppression of T cell or B cell activation or survival. Other genes influence clearance of immune complexes (complement components C1q, C4 and C2 mentioned above, FcgammaRIIA, RIIA and RIIIB, CRP, and integrin alpha M [ITGAM]). The HR for predisposing",
"    <span class=\"nowrap\">",
"     HLA-DR/DQ",
"    </span>",
"    is approximately 2.4, and is increased in patients homozygous for predisposing alleles, indicating a gene dose effect. HR for other genes varies from 1.2 to 2.3, with additional reports of significant, but relatively low HR-conferring, genes occurring at a rapid pace. In some cases, the genetic component is found in promoter regions (eg, IL-10), or is conferred by a variation in gene copy number rather than by different alleles (eg, FcgammaR3 and complement C4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, except for the rare TREX1 mutation or deficiencies of early components of complement, there is not a single gene polymorphism that creates high risk for SLE. Thus, a combination of susceptibility genes, or presence of susceptibility genes plus the absence of protective genes (such as TLR5 polymorphism or loss-of-function PTPN22 variant) are required to \"achieve\" enough genetic susceptibility to permit disease development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to genome-encoded susceptibility genes, epigenetic modifications are likely to be important in pathogenesis of SLE. These include hypomethylation of DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/65\">",
"     65",
"    </a>",
"    ], which influences transcription into protein. The influence of microRNAs (miRNA) on transcription of several SLE-predisposing genes has also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. &nbsp;The hypomethylation likely affects specific genes. &nbsp;",
"   </p>",
"   <p>",
"    Some of the single-nucleotide polymorphisms (SNPs) in SLE risk genes predispose to particular clinical subsets of SLE. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SNP in the third intron of STAT4 (which predisposes to both rheumatoid arthritis and to SLE in several ethnic groups) increases risk for anti-DNA antibodies, nephritis and the antiphospholipid syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/68-71\">",
"       68-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SNPs associated with LYN decrease risk for SLE susceptibility and for hematologic manifestations in European-American cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A CRP-A allele is associated with SLE nephritis but is inversely correlated with arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The polymorphism of FcgammaRIIa associated with low binding of immune complexes predisposes to lupus nephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/73-75\">",
"       73-75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A coding variant of the ITGAM gene is associated with the development of renal disease, discoid rash and &ldquo;immunological manifestations&rdquo; in patients with systemic lupus erythematosus with European ancestry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stratification by disease phenotypes may be of benefit in genetic analyses of molecular pathogenesis. A GWAS of SLE patients stratified by ancestry and extremes of phenotype in serology and serum IFNa, and using a multi-step screening approach, identified several loci of particular interest; each of these demonstrated a strong association with increased serum IFNa and with a particular serologic profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/77\">",
"     77",
"    </a>",
"    ]. These included LRRC20 and PPM1H (both with anti-La), LPAR1 (with anti-Ro and &ndash;Sm), ANKS1A (with anti-Ro and anti-dsDNA), and VSIG2 (with anti-RNP, but lacking anti-Sm). Additionally, SNPs in both PTPRM and LRRC20 were associated with increased serum IFNa independent of serologic profile. The findings demonstrate heterogeneity in SLE molecular pathogenesis and indicate the potential importance of these variants for subphenotypes of SLE, because none of the SNPs were strongly associated with SLE in case-control analysis.",
"   </p>",
"   <p>",
"    Genes on different chromosomes are also associated with clinical subsets such as nephritis (2q34), hemolytic anemia (11q14), discoid lupus and thrombocytopenia (11p13), vitiligo (17p12); to production of certain autoantibodies (eg, anti-ds DNA [19p13.2]); or to increased risk for end stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/44,78\">",
"     44,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hormonal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial evidence of the immunoregulatory function of estradiol, testosterone, progesterone, DHEA, and pituitary hormones, including prolactin, has supported the hypothesis that they modulate the incidence and severity of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of estrogen-containing contraceptive agents is associated with a 50 percent increase in risk of developing SLE; while either early onset of menarche (age &le;10 years) or administration of estrogen to postmenopausal women doubles their risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of women with clinically stable SLE with oral contraceptives for one year does not increase disease flares [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. However, treatment of postmenopausal women with hormone replacement may increase flares, although evidence is mixed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/17,83\">",
"       17,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SLE has been observed in some males with Klinefelter's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/16\">",
"       16",
"      </a>",
"      ]. This may be due to hormonal effects, including the lack of adequate androgenic hormones, other effects related to the presence in these patients of two X chromosomes, or both of these factors; the precise cause has not been determined.",
"     </li>",
"     <li>",
"      Altered sex hormone levels may predispose to the development of SLE or result from the autoimmune process. However, it is important to emphasize that hormone levels remain within the physiologic range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/79\">",
"       79",
"      </a>",
"      ]. In women, plasma levels of the following hormones are decreased: testosterone, progesterone, and dehydroepiandrosterone (DHEA), while estradiol and prolactin are increased. In men there are limited data that suggest that DHEA is probably decreased and prolactin increased, while testosterone and estradiol are unchanged.",
"     </li>",
"     <li>",
"      Breastfeeding may decrease risk of developing SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/15,84\">",
"       15,84",
"      </a>",
"      ], although evidence is mixed. It is clear that neither breastfeeding nor the duration of breastfeeding increase risk of developing SLE.",
"     </li>",
"     <li>",
"      The finding that nulliparous women are at higher risk of SLE than are women who have given birth at least once may suggest a role for hormonal influences, but the observed difference could also arise as a result of the higher rates of spontaneous abortions, missed abortions, and stillbirths in women with SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the possible effect of sex hormones on SLE, the clinical expression of the disease is the same in men and women.",
"   </p>",
"   <p>",
"    Studies of lupus-prone mice show different roles of estrogen and testosterone, depending upon the genetic background of the mouse strain. A lupus-like disease of F1 New Zealand",
"    <span class=\"nowrap\">",
"     Black/White",
"    </span>",
"    hybrid mice is more severe, has an earlier onset in females, and is ameliorated by oophorectomy, or treatment with male hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/86\">",
"     86",
"    </a>",
"    ]. Other strains of mice with a lupus-like disease, such as",
"    <span class=\"nowrap\">",
"     MRL/Fas-/-",
"    </span>",
"    do not have as marked gender differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/87\">",
"     87",
"    </a>",
"    ]. BXSB mice have lupus-like disease primarily in males, probably due to translocation of the gene encoding TLR7 from the X to the Y chromosome with resultant increased gene copies in males. In XX females, the locus is probably silenced on the inactive X, but in XY males the Y loci also encode TLR7, thus increasing expression with increased autoantibody formation to RNA-containing self antigens (which activate innate immunity via TLR7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Thus, the effect may not be hormonal in this instance, but related to genetic contributions on the X and Y chromosomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with peripheral blood cells of men, those from women produce significantly higher IFN-alpha (but not TNF-alpha) after TLR-7 stimulation, but not after TLR-9 stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since upregulation of genes controlled by IFN-alpha is characteristic of some SLE patients, particularly during active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/91\">",
"     91",
"    </a>",
"    ], this may be an important difference accounting for increased susceptibility of females to SLE.",
"   </p>",
"   <p>",
"    The etiologic role of hormones in SLE may be related to their effects on immune responsiveness. Estrogen stimulates thymocytes, CD8+ and CD4+ T cells, B cells, macrophages, the release of certain cytokines (eg, interleukin-1), and the expression of both HLA and endothelial cell adhesion molecules (VCAM, ICAM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/92\">",
"     92",
"    </a>",
"    ]. Estrogen also causes increased macrophage proto-oncogene expression and enhanced adhesion of peripheral mononuclear cells to endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/92\">",
"     92",
"    </a>",
"    ]. Another potentially important effect of estradiol may be its ability to reduce apoptosis in self-reactive B cells, thus promoting selective maturation of autoreactive B cells with high affinity for anti-DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/93\">",
"     93",
"    </a>",
"    ]. Consequently, women are predisposed to make autoantibodies that eventually lead to clinically apparent SLE. In comparison, androgens tend to be immunosuppressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/94\">",
"     94",
"    </a>",
"    ]. Serum levels of DHEA, an intermediate compound in testosterone synthesis, are low in nearly all patients with SLE. This may be mediated by impaired IL-2 production in SLE patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progesterone and prolactin also affect immune activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Progesterone downregulates T cell proliferation and increases the number of CD8 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/96\">",
"     96",
"    </a>",
"    ], while lupus flares have been associated with hyperprolactinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/98\">",
"     98",
"    </a>",
"    ]. In addition, both progesterone and high levels of estrogen promote a Th2 response, which favors autoantibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an increased incidence of thyroid disease in patients with SLE. In one study of 41 patients with SLE, for example, the incidence of both antithyroid antibodies (51 versus 27 percent) and elevated serum TSH levels (24 versus 12 percent) were higher than in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/99\">",
"     99",
"    </a>",
"    ]. In another study of 319 patients, nine had thyrotoxicosis, three had hypothyroidism, and two had thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities of the hypothalamus-pituitary-adrenal axis may also exist among those with SLE. Patients appear to have an abnormal reaction to stress characterized by a heightened response to human corticotropin releasing hormone (hCRH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/101\">",
"     101",
"    </a>",
"    ]. However, non-hormonal factors may play a role in the excess of lupus in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immune abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary, and which are secondarily induced. In certain cases these immune defects are episodic, and some correlate with disease activity.",
"   </p>",
"   <p>",
"    SLE is primarily a disease with abnormalities in immune regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. These abnormalities are thought to be secondary to a loss of self tolerance; thus, affected patients (either before or during disease evolution) are no longer totally tolerant to all of their self-antigens, and consequently develop an autoimmune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mediators of SLE are autoantibodies and immune complexes they form with antigens; the autoantibodies may be present for years before the first symptom of disease appears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/108\">",
"     108",
"    </a>",
"    ]. Self-antigens that are recognized are presented primarily on cell surfaces, particularly by cells that are activated or undergoing apoptosis, where intracellular antigens access cell surfaces where they can be recognized by the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. To form immune complexes, antigens have to leave, versus be &ldquo;released from&rdquo;, cells.",
"   </p>",
"   <p>",
"    Phagocytosis and clearing of immune complexes, of apoptotic cells, and of necrotic cell-derived material are defective in SLE, allowing persistence of antigen and immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/111\">",
"     111",
"    </a>",
"    ]. B",
"    <span class=\"nowrap\">",
"     cells/plasma",
"    </span>",
"    cells that make autoantibodies are more persistently activated and driven to maturation by B cell activating factor (BAFF, also known as B lymphocyte stimulator, BLyS) and by persistently activated T helper cells making B-supporting cytokines such as IL-6 and IL-10. BAFF (BLyS), serum levels of which are elevated in some patients with SLE, promotes formation and survival of memory B cells and plasmablasts. This increased autoantibody persistence is not downregulated appropriately by anti-idiotypic antibodies, or by CD4+CD25hi-Foxp3+ regulatory T cells, or by CD8+ suppressor T cells.",
"   </p>",
"   <p>",
"    As mentioned earlier, some",
"    <span class=\"nowrap\">",
"     antibody/antigen",
"    </span>",
"    complexes, particularly those containing DNA or",
"    <span class=\"nowrap\">",
"     RNA/proteins,",
"    </span>",
"    activate the innate immune system via TLR-9 or TLR-7, respectively. Thus, dendritic cells are activated and release type 1 interferons and TNF-alpha, T cells release IFN-gamma, IL6, IL10, while NK and T cells fail to release adequate quantities of TGF-beta. These cytokine patterns favor continued autoantibody formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The innate immune system may also be activated by infections (bacterial or RNA- or DNA-containing viruses). Thus both innate and adaptive immunity conspire to continually produce autoantibodies; that response is regulated for a few years; if regulation fails, clinical disease results.",
"   </p>",
"   <p>",
"    The following are some of the immune abnormalities that have been described in SLE which relate to the vicious cycle described in the preceding discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in circulating plasma cells (the producers of autoantibodies) and of a subset of memory B cells, is associated with disease activity in SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decrease in cytotoxic T cells and in functions of suppressor T cells (which would normally downregulate immune responses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/107,115\">",
"       107,115",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired generation of polyclonal T cell cytolytic activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/116\">",
"       116",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increase in helper (CD4+) T cells and helper function by both CD4+ and CD8+ T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/117,118\">",
"       117,118",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polyclonal activation of B cells and abnormal B cell receptor signaling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/119,120\">",
"       119,120",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Defects in B cell tolerance, perhaps related to defects in apoptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complement deficiency, lead to prolonged lives of B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/107,121-123\">",
"       107,121-123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased BAFF (BLyS) expression may promote autoimmunity. B cells have three receptors for BAFF: BAFFR, BCMA, and TACI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/124\">",
"       124",
"      </a>",
"      ]. BAFF, which is produced primarily by neutrophils and",
"      <span class=\"nowrap\">",
"       monocyte/macrophages,",
"      </span>",
"      increases survival of B2 cells after their transitional T1 phase (which means the B cells have survived several deleting and anergizing tolerance mechanisms), as well as survival of resting memory B cells and plasmablasts. Stimulation by BAFF is particularly important for the survival of T-dependent B cells, the source of many autoantibodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Increased BAFF (BLyS) production is promoted by increased TLR activation and increased type 1 and 2 interferons; in turn, BAFF promotes increased TLR activation. Thus, BAFF can contribute to sustained autoantibody production by several mechanisms. Clinical trials have demonstrated that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       belimumab",
"      </a>",
"      , a monoclonal antibody to BAFF, may be beneficial for the treatment of patients with SLE, for whom its use has been approved by the FDA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/125,126\">",
"       125,126",
"      </a>",
"      ]. A proliferation-inducing ligand (APRIL), made primarily by dendritic cells, binds a transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) and an additional B cell receptor, B cell maturation antigen (BCMA). In some conditions, APRIL promotes B cell survival and in others can provide a negative signal. Biologic therapies are in development that will inhibit the effects of both BAFF and APRIL.",
"     </li>",
"     <li>",
"      Dysfunctional signaling in T and B cells, which is manifested by increased calcium responses to antigen stimulation, hyperphosphorylation of cytosolic protein substrates, decreased nuclear factor kB, and abnormal voltage-gated potassium (Kv1.3) channels are implicated in facilitating excessive calcium entry into T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/120,127,128\">",
"       120,127,128",
"      </a>",
"      ]. These changes probably account for the decreased IL-2 production of lupus T cells, which might contribute to inability to generate adequate numbers of functioning regulatory T cells.",
"     </li>",
"     <li>",
"      Increased fetal microchimerism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/129\">",
"       129",
"      </a>",
"      ] providing \"foreign\" antigens to the immune system.",
"     </li>",
"     <li>",
"      Elevated circulating levels of interferon alpha and increased expression of interferon alpha-inducible RNA transcripts by mononuclear cells, especially in patients with active disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/130-135\">",
"       130-135",
"      </a>",
"      ]. The elevated levels of interferon alpha and increased expression of alpha-interferon inducible transcripts may be due in part to the presence of predisposing genetic factors affecting interferon expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/136\">",
"       136",
"      </a>",
"      ]. A similar increase in interferon alpha-inducible transcripts occurs in synovial tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/137\">",
"       137",
"      </a>",
"      ]. Patients with the SLE-risk enhancing PTPN22 C1858T allele are more likely to have elevated circulating INF-alpha, which may contribute to inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with SLE treated with antimalarials, a genotype associated with low TNF and high IL-10 levels correlated with higher serum concentrations of IFN-alpha, while those with high TNF-alpha and low IL-10 levels had increased numbers of regulatory T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/138\">",
"       138",
"      </a>",
"      ]. The relative contributions of IFN and TNF to various aspects of SLE activity are poorly understood.",
"     </li>",
"     <li>",
"      Abnormally high levels of erythrocyte C4-derived activation fragments (C4d) and low levels of erythrocyte complement receptor (CR1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/139\">",
"       139",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal toll-like receptor (TLR)-7 signaling in response to RNA and TLR-9 signaling in response to DNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/140,141\">",
"       140,141",
"      </a>",
"      ] and increased expression of TLR-9 on peripheral blood B cells and plasma cells and dendritic cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/140,142-146\">",
"       140,142-146",
"      </a>",
"      ]. This means that B cells can be activated to secrete autoantibody by the innate immune system, independent of T cell help.",
"     </li>",
"     <li>",
"      Stimulation of TLR7 or TLR9 reduces the immunosuppressive activity of glucocorticoids, suggesting that nucleic acid containing immune complexes that induce TLR signaling may limit effectiveness of glucocorticoids and may account for the high doses required for therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/147\">",
"       147",
"      </a>",
"      ]. Correspondingly, blocking stimulation of TLR7 or 9 may be useful therapeutically and restore sensitivity to glucocorticoids.",
"     </li>",
"     <li>",
"      Higher expression of TLR-9 on B cells as well as low CH50 levels associated with increased SLE Disease Activity Index (SLEDAI) scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/144\">",
"       144",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased serum levels of HMGB1 (high mobility group box chromosomal protein 1) in patients with SLE is associated with disease activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/148\">",
"       148",
"      </a>",
"      ]. Whether this is specific for SLE is as yet not clear; antibodies to HMG have been noted in patients with juvenile idiopathic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/149\">",
"       149",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42695?source=see_link\">",
"       \"Miscellaneous antinuclear antibodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes promote the production of antinuclear antibodies (ANA, see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/150\">",
"     150",
"    </a>",
"    ]. In addition, certain strains of mice (ie, those with the lpr mutation) have a genetic defect in apoptosis, resulting in abnormal programmed cell death that allows the development of autoreactivity and the dramatic increase in an aberrant lymphoid population. Humans with a comparable mutation (ie, autoimmune lymphoproliferative syndrome) display abnormal lymphoproliferation in association with cytopenias and autoimmunity. In humans with lupus, abnormalities in extent of apoptosis or the clearance of apoptotic cells may also occur, although studies on human lupus primarily involve analysis of peripheral blood cells in which immune activation can lead to cell death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=see_link&amp;anchor=H9#H9\">",
"     \"Apoptosis and autoimmune disease\", section on 'Autoimmune lymphoproliferative syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, mice with lupus and possibly humans have a (genetic) defect in apoptosis, resulting in abnormal programmed cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/109,110,151,152\">",
"     109,110,151,152",
"    </a>",
"    ]. Apoptotic cells, often with nuclear antigens expressed on their surface in blebs, and cell fragments are also poorly cleared in SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/153\">",
"     153",
"    </a>",
"    ]. C1q and antiphospholipid antibodies enhance opsonization and clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/154-157\">",
"     154-157",
"    </a>",
"    ]; thus, depressed levels of C1q and C4 may impair phagocytosis and delay clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/158,159\">",
"     158,159",
"    </a>",
"    ]. The act of phagocytosis results in a stimulation of the immune response to autoantigens derived from the apoptotic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/160,161\">",
"     160,161",
"    </a>",
"    ]. In addition, protein cleavage by caspases and granzyme B may promote the antigenicity of the contents of apoptotic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, Toll-like-receptors (TLR)-7 and TLR-9 may play a role in promoting autoimmunity. Lupus-prone mice deficient in TLR 9 have an abnormal immune response to microbial CpG DNA and have an inhibition of anti-dsDNA and anti-chromatin antibodies but still develop nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/162\">",
"     162",
"    </a>",
"    ]. In this context, it is interesting that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (which is one of the causes of drug-induced lupus) blocks CpG methylation and antimalarial drugs used to treat some manifestations of SLE (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ) may block TLR 7 and 9 signaling. TLR 7 and 9 are involved in the interferon alpha response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/163\">",
"     163",
"    </a>",
"    ], and immune complexes containing",
"    <span class=\"nowrap\">",
"     DNA/autoantibody",
"    </span>",
"    activate dendritic cells through cooperation of CD32 and TLR-9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/145\">",
"     145",
"    </a>",
"    ]; similarly RNA-containing self antigens can activate dendritic cells through TLR-7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/146\">",
"     146",
"    </a>",
"    ], both by innate immune stimulation via TLR7 (recognizes RNA) and TLR9 (recognizes DNA) which can directly stimulate B cells to make autoantibodies, and by T cell stimulation of B cells via adaptive immunity as well as activating the INF-a response (see below).",
"   </p>",
"   <p>",
"    These multiple defects cause a cascade of events that begins with abnormal cellular breakdown, and ends with the production of autoantibodies. As cells break down abnormally, certain (especially nuclear and cryptic self peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/164\">",
"     164",
"    </a>",
"    ]) antigens are processed (perhaps abnormally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/165,166\">",
"     165,166",
"    </a>",
"    ]) into peptides by antigen-presenting cells (APCs) such as macrophages, B lymphocytes, and dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,167\">",
"     106,167",
"    </a>",
"    ]. Alternatively, microorganisms may be broken down within APCs into \"mimicry peptides\" that have sufficient structural similarity with immunodominant self peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With either mechanism, a peptide-MHC complex forms and stimulates the activation and clonal expansion of CD4+ autoreactive T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/168\">",
"     168",
"    </a>",
"    ]. These cells, via release of cytokines (eg, interleukin-4, interleukin-6 and interleukin-10) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,169\">",
"     106,169",
"    </a>",
"    ], cause autoreactive B cells to become activated, proliferate, and differentiate into antibody-producing cells that make an excess of antibodies to many nuclear antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,167\">",
"     106,167",
"    </a>",
"    ]. At the same time, activation of the innate immune system with release of IL-1, TNFa, type 1 interferons, BAFF (BLyS) and APRIL promotes inflammation and survival of autoreactive B cells. Thus, a specific immune profile develops that is characterized by the development of elevated levels of antinuclear antibodies, especially to DNA, Sm, RNP, Ro, La, nucleosomes, and other nuclear antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,170,171\">",
"     106,170,171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antinuclear antibodies are made to antigens from active sites on molecules involved in essential cellular functions (such as RNA splicing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/172\">",
"     172",
"    </a>",
"    ]. With continued pressure over time from self-antigens, the immune response switches, via somatic hypermutation, from low affinity, highly cross-reactive IgM antibodies, to high affinity IgG antibodies, and then finally to antibodies directed toward more limited epitopes on self-antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/173\">",
"     173",
"    </a>",
"    ]. Unique idiotypes of antibodies may then stimulate autoreactive T cells to expand, thereby helping unique clones of B cells to expand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/174\">",
"     174",
"    </a>",
"    ]. The final result is the production of more specific antinuclear antibodies with unique idiotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/175\">",
"     175",
"    </a>",
"    ]. These antinuclear antibodies may precede clinical manifestations by years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/108,176\">",
"     108,176",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all autoantibodies cause disease. In fact, all normal individuals make autoantibodies, although in small quantities. The variability in clinical disease that exists among different patients may therefore reflect the variability in the quality and quantity of the immune response, including regulatory networks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The environment probably has a role in the etiology of SLE via its effects on the immune system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viruses, for example, may stimulate specific cells in this immune network [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106,177,178\">",
"       106,177,178",
"      </a>",
"      ]. In addition, trypanosomiasis or mycobacterial infections may induce anti-DNA antibodies or even lupus-like symptoms, and lupus flares may follow bacterial infections (perhaps related to bacterial CpG motifs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/127,150\">",
"       127,150",
"      </a>",
"      ]. Patients with SLE also have higher titers of antibodies to Epstein-Barr virus (EBV), have increased circulating EBV viral loads, and make antibodies to retroviruses, including to protein regions homologous to nuclear antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/179,180\">",
"       179,180",
"      </a>",
"      ]. In fact, studies in children with SLE suggest that EBV infection may be a triggering event resulting in clinical SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/179\">",
"       179",
"      </a>",
"      ]. Antibodies to these molecular mimicry molecules may contribute to the development of autoimmunity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/181\">",
"       181",
"      </a>",
"      ]. Endogenous retroviruses have also been postulated to trigger lupus through structural and functional molecular mimicry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultraviolet (UV) light may stimulate keratinocytes to express more snRNPs on their cell surface [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/183,184\">",
"       183,184",
"      </a>",
"      ] and to secrete more IL-1, IL-3, IL-6, GM-CSF, and TNF-alpha, thereby stimulating B cells to make more antibody. In addition to the local effects in skin, UV light may also increase the degree of systemic autoimmunity by interfering with antigen processing by and activation of macrophages. UV light decreases T cell DNA methylation, which may lead to overexpression of LFA-1 (lymphocyte function-associated antigen-1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/185\">",
"       185",
"      </a>",
"      ]. These T cells may then become autoreactive, resulting in autoantibody formation.",
"     </li>",
"     <li>",
"      Silica dust, found in cleaning powders, soil, pottery materials, cement, and cigarette smoke may increase the risk of developing SLE, especially in African American women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/14,186-190\">",
"       14,186-190",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allergies to medications, particularly to antibiotics, are reported more frequently in patients with newly diagnosed SLE than healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/178\">",
"       178",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a slight, but significantly higher, prevalence of lupus in pet dogs of patients with SLE (3 cases among 59 pet dogs owned by 37 SLE patients, versus none among 187 dogs in non-SLE households) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/191\">",
"       191",
"      </a>",
"      ]. These observations suggest a possible common environmental factor for both human and dog systemic lupus.",
"     </li>",
"     <li>",
"      There is no apparent association between SLE and the use of hair dyes, occupational solvent exposure, the use of pesticides, or alcohol consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/188,192\">",
"       188,192",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of studies of alcohol use and SLE risk concluded that moderate alcohol consumption had a protective effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/193\">",
"       193",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the exact etiology of SLE remains obscure, it is clear that many of the clinical manifestations of SLE are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). As an example, immune complex deposition and subsequent complement activation in the kidney is responsible for much of the tissue damage of lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .) IC have also been detected (by immunofluorescence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electron microscopy) at the dermal-epidermal junction in both skin lesions and normal skin, and in the choroid plexus, the pericardium, and the pleural cavity.",
"   </p>",
"   <p>",
"    The pathogenic potential of IC varies, depending on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristics of the antibody, such as its specificity, affinity, charge, and ability to activate complement or other mediator of inflammation. In the glomerulus, for example, different antibodies may bind to antigens at different sites in the glomerular capillary wall, leading to different histologic and clinical manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/194,195\">",
"       194,195",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nature of the antigen, such as its size and charge. Smaller cationic antigens, for example, are more able to cross the glomerular basement membrane and be deposited in the subepithelial cell. The ensuing formation of IC should lead to membranous nephropathy rather than a proliferative glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ability of the IC to be solubilized by complement and bound to the CR1 receptors on red blood cells (both systems may be defective in SLE).",
"     </li>",
"     <li>",
"      The rate at which the IC are cleared by immunoglobulin Fc receptors on",
"      <span class=\"nowrap\">",
"       monocytes/macrophages",
"      </span>",
"      in the liver and spleen from the circulation may be genetically impaired in SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/196\">",
"       196",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of renal disease in SLE is likely due to the deposition or formation of immune complexes in the mesangium, subendothelial or subepithelial spaces, with subsequent activation of complement.",
"   </p>",
"   <p>",
"    Immune complexes (IC) in this disease consist of nuclear antigens (especially DNA), and high-affinity, complement-fixing IgG antinuclear antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/197\">",
"     197",
"    </a>",
"    ] (especially IgG1 and IgG3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/198\">",
"     198",
"    </a>",
"    ]), and antibodies to DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/199\">",
"     199",
"    </a>",
"    ]. These complexes either form in the circulation, where they are poorly cleared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/200\">",
"     200",
"    </a>",
"    ] or form in situ as free antibody binds to free antigen that has already deposited in the glomerulus or is an intrinsic glomerular antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/201\">",
"     201",
"    </a>",
"    ]. Histones have high affinity for the glomerular basement membrane (GBM) and may facilitate IC deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/202\">",
"     202",
"    </a>",
"    ]. Antibody reactivities in the serum that best correlate with active nephritis in human SLE are directed against",
"    <span class=\"nowrap\">",
"     DNA/chromatin",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     laminin/myosin/vimentin/heparan",
"    </span>",
"    sulphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/203\">",
"     203",
"    </a>",
"    ], suggesting the importance of these reactivities to pathogenesis.",
"   </p>",
"   <p>",
"    Elevated levels of anti-DNA antibodies commonly precede development of clinical lupus nephritis. This was illustrated in a study of serum samples collected from military recruits. Among those who developed SLE and renal disease, 92 percent had positive anti-double stranded DNA antibodies present before diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/176\">",
"     176",
"    </a>",
"    ]. In addition, the combination of a rising level (titer) of anti-DNA and evidence of increased complement activation (eg, rising C3a), if detected, may allow preemptive treatment and avoid lupus flares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/204\">",
"     204",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once deposited in the mesangial or subendothelial aspect of the GBM, immune complexes activate the complement system, thereby generating chemotactic factors that attract the infiltration of leukocytes and mononuclear cells. These cells phagocytose IC and release mediators (such as cytokines and activators of the clotting system) that perpetuate glomerular inflammation. With continuing IC deposition, chronic inflammation may ensue, ultimately leading to fibrinoid necrosis, scarring, and reduced renal function.",
"   </p>",
"   <p>",
"    Although necessary, immune complex deposition and complement activation do not appear to be sufficient to initiate the development of chronic inflammation in lupus nephritis. As an example, the significance of the gamma chain of the immunoglobulin Fc receptor was assessed via its deletion in a strain of mice, the New Zealand",
"    <span class=\"nowrap\">",
"     Black/New",
"    </span>",
"    Zealand White, in which severe nephritis normally develops spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/205\">",
"     205",
"    </a>",
"    ]. Nephritis was completely prevented in the gamma chain-deficient mice despite immune complex deposition and complement activation, thereby suggesting an uncoupling of activation of the immune system from ongoing complement activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/205\">",
"     205",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, in situ antibody deposition occurring in the subepithelial space in lupus membranous nephropathy is not associated with inflammation. In this setting, complement is activated at a site that is separated from circulating inflammatory cells by the GBM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/206\">",
"     206",
"    </a>",
"    ]. As a result, these patients develop epithelial cell injury and proteinuria but not active inflammation and glomerulonephritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cell-surface antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE patients make antibodies to a number of cell-surface antigens. Antibodies to a 66-kDa membrane antigen have been implicated in lupus nephritis, vasculitis and hypocomplementemia; to a 55-kDa antigen in thrombocytopenia; and to a 18-kDa protein in thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/207\">",
"     207",
"    </a>",
"    ], and antibodies to neuronal cells in organic brain disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .) Cell-surface antibodies also attach to red blood cells, white blood cells, and platelets. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .) In addition, antinuclear antibodies may interact with nuclear antigens expressed on cell surfaces, triggering cell injury and even death, either by activating complement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by cell penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/208\">",
"     208",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These complexes are cleared from the circulation, and may cause organ damage, through one of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fc receptors on macrophages of the reticuloendothelial system",
"     </li>",
"     <li>",
"      Complement-mediated cytotoxicity",
"     </li>",
"     <li>",
"      Antibody-dependent cellular cytotoxicity (ADCC) resulting in hemolytic anemia, leukopenia, and thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE may form antibodies to a phospholipid-beta-2 glycoprotein I complex. Beta-2-glycoprotein I normally has an anticoagulant effect that is diminished by this antibody formation. This may explain why antiphospholipid antibodies are implicated in the etiology of the arterial and venous thromboses (causing strokes and thrombophlebitis), and in placental infarcts (causing miscarriages). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiphospholipid antibodies, like antinuclear antibodies, may be present prior to the diagnosis of SLE. This was illustrated in a study of a cohort of 130 patients for whom stored serum samples that preceded the SLE diagnosis were available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/102\">",
"     102",
"    </a>",
"    ]. The presence of anticardiolipin antibodies was noted in 24 patients who later developed SLE, and in these patients, developed an average of three years prior to the diagnosis of SLE. Furthermore, the patients with anticardiolipin antibodies tended to develop more severe lupus than those without these antiphospholipid antibodies. Eleven patients with anticardiolipin antibodies developed thrombotic events prior to the diagnosis of SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions are thought to be multifactorial in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/209\">",
"     209",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .) In particular, exposure to UV light has a number of local effects in the skin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It damages DNA. The patient can then make antibodies to DNA, IC form, complement is activated, and a local inflammatory response ensues.",
"     </li>",
"     <li>",
"      It increases binding of anti-Ro, anti-La, and anti-RNP antibodies to UV-activated keratinocytes, which express those antigens in apoptotic blebs on the cell surface [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/210\">",
"       210",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It alters cellular membrane phospholipid metabolism. Portions of cell membranes may be rearranged so the usually cytoplasmic-facing surfaces (and potentially antigenic molecules) are on the extracellular surface.",
"     </li>",
"     <li>",
"      It increases IL-1 release from cutaneous keratinocytes and Langerhans cells.",
"     </li>",
"     <li>",
"      It increases apoptosis of keratinocytes in patients with SLE and healthy persons; but clearance of apoptotic cells by phagocytes is abnormal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/211\">",
"       211",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, in addition to the local effects in skin, UV light may also increase the degree of autoimmunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/43/37562/abstract/185\">",
"     185",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443498\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of systemic lupus erythematosus (SLE) is 20 to 150 cases per 100,000; rates in women vary from 164 (white) to 406 (African American) per 100,000. The estimated incidence is 1 to 25 per 100,000 in North America, South America, Europe, and Asia. Both geography and race affect the prevalence of SLE and the frequency and severity of clinical and laboratory manifestations. The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Geographic and racial distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease onset is between the ages of 16 and 55 in 65 percent of patients, but disease also occurs in both children and older individuals. Different epidemiologic subgroups, including those based upon",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      gender, and age of onset, tend to have varying degrees of disease activity and may differ in their prevalence of given clinical manifestations, which may affect disease outcome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Age at onset'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Factors affecting disease outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of SLE remains unknown and is clearly multifactorial. Many observations suggest a role for genetic, hormonal, immunologic, and environmental factors. There is no single gene polymorphism that creates high risk for SLE, except for the rare TREX1 mutation or deficiencies of early components of complement. A combination of susceptibility genes, or presence of susceptibility genes plus the absence of protective genes are required for sufficient genetic susceptibility to permit disease development. Epigenetic modifications are also likely to be important. Additionally, some of the single-nucleotide polymorphisms in SLE risk genes predispose to particular clinical subsets of SLE. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substantial evidence of the immunoregulatory function of estradiol, testosterone, progesterone, DHEA, and pituitary hormones, including prolactin, has supported the hypothesis that these hormones modulate the incidence and severity of SLE. There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary, and which are secondarily induced. In certain cases these immune defects are episodic, and some correlate with disease activity. The environment probably has a role in the etiology of SLE via its effects on the immune system. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hormonal factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Immune abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Environmental factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is clear that many of the clinical manifestations are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). Initiation of renal disease in SLE is likely due to the deposition or formation of IC in the mesangium, subendothelial or subepithelial spaces, with subsequent activation of complement. SLE patients make antibodies to a number of cell-surface antigens, such as those to a phospholipid-beta-2 glycoprotein I complex; these antibodies are involved in thromboembolic events and obstetric complications. Skin lesions are thought to be multifactorial in origin; UV light has local effects in skin and may increase the degree of autoimmunity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis of clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Renal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Cell-surface antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Antiphospholipid antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/1\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/2\">",
"      Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/3\">",
"      Pons-Estel GJ, Alarc&oacute;n GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/4\">",
"      Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/5\">",
"      Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15:308.",
"     </a>",
"    </li>",
"    <li>",
"     Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus, Wallace DJ, Hahn BH (Eds), Lippincott Williams and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/7\">",
"      Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/8\">",
"      Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/9\">",
"      Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985; 28:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/10\">",
"      Serdula MK, Rhoads GG. Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii. Arthritis Rheum 1979; 22:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/11\">",
"      Symmons DP. Frequency of lupus in people of African origin. Lupus 1995; 4:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/12\">",
"      Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983; 42:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/13\">",
"      Chung SA, Tian C, Taylor KE, et al. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis Rheum 2009; 60:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/14\">",
"      Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/15\">",
"      Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007; 56:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/16\">",
"      Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/17\">",
"      Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/18\">",
"      Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/19\">",
"      Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 2008; 58:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/20\">",
"      Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006; 176:7143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/21\">",
"      Lockshin MD. Sex differences in autoimmune disease. Lupus 2006; 15:753.",
"     </a>",
"    </li>",
"    <li>",
"     Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/23\">",
"      Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/24\">",
"      Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/25\">",
"      Fern&aacute;ndez M, Alarc&oacute;n GS, Calvo-Al&eacute;n J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/26\">",
"      Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 1990; 150:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/27\">",
"      Reveille JD, Bartolucci A, Alarc&oacute;n GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/28\">",
"      Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/29\">",
"      Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/30\">",
"      Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991; 91:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/31\">",
"      Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among \"Hispanics\". Medicine (Baltimore) 2004; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/32\">",
"      Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/33\">",
"      Johnson AE, Cavalcanti FS, Gordon C, et al. Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus 1994; 3:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/34\">",
"      Lu LJ, Wallace DJ, Ishimori ML, et al. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/35\">",
"      Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/36\">",
"      Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD. Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 1989; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/37\">",
"      Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine (Baltimore) 1983; 62:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/38\">",
"      Ward MM, Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol 1990; 17:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/39\">",
"      Prete PE, Majlessi A, Gilman S, Hamideh F. Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population. J Clin Rheumatol 2001; 7:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/40\">",
"      Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989; 32:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/41\">",
"      Boddaert J, Huong DL, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004; 83:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/42\">",
"      Lalani S, Pope J, de Leon F, et al. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol 2010; 37:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/43\">",
"      Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/44\">",
"      Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol 2006; 28:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/45\">",
"      Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 2006; 28:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/46\">",
"      Block SR, Winfield JB, Lockshin MD, et al. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med 1975; 59:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/47\">",
"      Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/48\">",
"      Arnett FC, Reveille JD, Wilson RW, et al. Systemic lupus erythematosus: current state of the genetic hypothesis. Semin Arthritis Rheum 1984; 14:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/49\">",
"      Hunnangkul S, Nitsch D, Rhodes B, et al. Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. Arthritis Rheum 2008; 58:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/50\">",
"      Murashima A, Fukazawa T, Hirashima M, et al. Long term prognosis of children born to lupus patients. Ann Rheum Dis 2004; 63:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/51\">",
"      Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/52\">",
"      Graham RR, Hom G, Ortmann W, Behrens TW. Review of recent genome-wide association scans in lupus. J Intern Med 2009; 265:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/53\">",
"      Nath SK, Han S, Kim-Howard X, et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; 40:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/54\">",
"      Barcellos LF, May SL, Ramsay PP, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009; 5:e1000696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/55\">",
"      International MHC and Autoimmunity Genetics Network, Rioux JD, Goyette P, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009; 106:18680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/56\">",
"      Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/57\">",
"      Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/58\">",
"      Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008; 58:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/59\">",
"      Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/60\">",
"      Lazarus M, Hajeer AH, Turner D, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/61\">",
"      Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/62\">",
"      Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/63\">",
"      Hawn TR, Wu H, Grossman JM, et al. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005; 102:10593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/64\">",
"      Orr&uacute; V, Tsai SJ, Rueda B, et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009; 18:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/65\">",
"      Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/66\">",
"      Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/67\">",
"      Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/68\">",
"      Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/69\">",
"      Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008; 4:e1000084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/70\">",
"      Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/71\">",
"      Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/72\">",
"      Lu R, Vidal GS, Kelly JA, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun 2009; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/73\">",
"      J&ouml;nsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 2007; 46:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/74\">",
"      Kyogoku C, Tsuchiya N, Wu H, et al. Association of Fcgamma receptor IIA, but not IIB and IIIA, polymorphisms with systemic lupus erythematosus: A family-based association study in Caucasians. Arthritis Rheum 2004; 50:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/75\">",
"      Croker JA, Kimberly RP. Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/76\">",
"      Kim-Howard X, Maiti AK, Anaya JM, et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis 2010; 69:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/77\">",
"      Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/78\">",
"      Sestak AL, Nath SK, Sawalha AH, Harley JB. Current status of lupus genetics. Arthritis Res Ther 2007; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/79\">",
"      McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum 2003; 48:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/80\">",
"      Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum 2005; 52:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/81\">",
"      Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/82\">",
"      S&aacute;nchez-Guerrero J, Uribe AG, Jim&eacute;nez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/83\">",
"      S&aacute;nchez-Guerrero J, Gonz&aacute;lez-P&eacute;rez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/84\">",
"      Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002; 46:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/85\">",
"      Ulff-M&oslash;ller CJ, J&oslash;rgensen KT, Pedersen BV, et al. Reproductive factors and risk of systemic lupus erythematosus: nationwide cohort study in Denmark. J Rheumatol 2009; 36:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/86\">",
"      Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/87\">",
"      Mountz JD, Gause WC, Jonsson R. Murine models for systemic lupus erythematosus and Sj&ouml;gren's syndrome. Curr Opin Rheumatol 1991; 3:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/88\">",
"      Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 2006; 103:9970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/89\">",
"      Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/90\">",
"      Bergh&ouml;fer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/91\">",
"      Nikpour M, Dempsey AA, Urowitz MB, et al. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/92\">",
"      Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol 1995; 13:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/93\">",
"      Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006; 305:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/94\">",
"      Lahita RG. Sex hormones and the immune system--Part 1. Human data. Baillieres Clin Rheumatol 1990; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/95\">",
"      Suzuki T, Suzuki N, Engleman EG, et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 99:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/96\">",
"      Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/97\">",
"      Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/98\">",
"      Blanco-Favela F, Quintal-Alvarez G, Lea&ntilde;os-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/99\">",
"      Weetman AP, Walport MJ. The association of autoimmune thyroiditis with systemic lupus erythematosus. Br J Rheumatol 1987; 26:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/100\">",
"      Goh KL, Wang F. Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis 1986; 45:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/101\">",
"      Gl&uuml;ck T, Oertel M, Reber T, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis. J Rheumatol 2000; 27:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/102\">",
"      McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/103\">",
"      Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/104\">",
"      Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/105\">",
"      Hahn BH, Ebling F, Singh RR, et al. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 2005; 1051:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/106\">",
"      Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/107\">",
"      Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995; 144:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/108\">",
"      Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/109\">",
"      Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/110\">",
"      Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/111\">",
"      Mu&ntilde;oz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/112\">",
"      Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010; 69:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/113\">",
"      Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/114\">",
"      Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/115\">",
"      Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/116\">",
"      Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum 1995; 38:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/117\">",
"      Tsokos GC. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1995; 7:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/118\">",
"      Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/119\">",
"      Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/120\">",
"      Krishnan S, Chowdhury B, Tsokos GC. Autoimmunity in systemic lupus erythematosus: integrating genes and biology. Semin Immunol 2006; 18:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/121\">",
"      Mohan C, Datta SK. Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995; 77:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/122\">",
"      Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/123\">",
"      Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/124\">",
"      Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008; 223:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/125\">",
"      Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/126\">",
"      Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/127\">",
"      Steinberg AD. Insights into the basis of systemic lupus. J Autoimmun 1995; 8:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/128\">",
"      Tsokos GC. Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. Arthritis Rheum 2008; 58:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/129\">",
"      Abbud Filho M, Pavarino-Bertelli EC, Alvarenga MP, et al. Systemic lupus erythematosus and microchimerism in autoimmunity. Transplant Proc 2002; 34:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/130\">",
"      R&ouml;nnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/131\">",
"      Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/132\">",
"      Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/133\">",
"      Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/134\">",
"      Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/135\">",
"      Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010; 19:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/136\">",
"      Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/137\">",
"      Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/138\">",
"      L&oacute;pez P, G&oacute;mez J, Prado C, et al. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008; 35:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/139\">",
"      Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/140\">",
"      Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/141\">",
"      Goodnow CC. Immunology. Discriminating microbe from self suffers a double toll. Science 2006; 312:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/142\">",
"      Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/143\">",
"      Migita K, Miyashita T, Maeda Y, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/144\">",
"      Nakano S, Morimoto S, Suzuki J, et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/145\">",
"      Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/146\">",
"      Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/147\">",
"      Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/148\">",
"      Li J, Xie H, Wen T, et al. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/149\">",
"      Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J Rheumatol 2010; 37:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/150\">",
"      Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/151\">",
"      Aringer M, Wintersberger W, Steiner CW, et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/152\">",
"      Ohsako S, Hara M, Harigai M, et al. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994; 73:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/153\">",
"      Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006; 65:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/154\">",
"      Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/155\">",
"      Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/156\">",
"      Charles PJ. Defective waste disposal: does it induce autoantibodies in SLE? Ann Rheum Dis 2003; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/157\">",
"      Mevorach D. Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis 2010; 15:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/158\">",
"      Bijl M, Reefman E, Horst G, et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006; 65:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/159\">",
"      Munoz LE, Gaipl US, Franz S, et al. SLE--a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/160\">",
"      Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997; 185:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/161\">",
"      Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med 2009; 265:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/162\">",
"      Christensen SR, Kashgarian M, Alexopoulou L, et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/163\">",
"      Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/164\">",
"      Mamula MJ. Lupus autoimmunity: from peptides to particles. Immunol Rev 1995; 144:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/165\">",
"      Tsokos GC, Kovacs B, Sfikakis PP, et al. Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/166\">",
"      Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/167\">",
"      Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/168\">",
"      Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 1995; 181:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/169\">",
"      Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005; 17:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/170\">",
"      Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/171\">",
"      Chabre H, Amoura Z, Piette JC, et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/172\">",
"      Pisetsky DS. Autoantibodies and their significance. Curr Opin Rheumatol 1993; 5:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/173\">",
"      Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997; 40:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/174\">",
"      Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995; 96:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/175\">",
"      Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/176\">",
"      Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/177\">",
"      Blomberg J, Nived O, Pipkorn R, et al. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations. Arthritis Rheum 1994; 37:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/178\">",
"      Cooper GS, Dooley MA, Treadwell EL, et al. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002; 55:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/179\">",
"      James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/180\">",
"      James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/181\">",
"      Sekigawa I, Kaneko H, Hishikawa T, et al. HIV infection and SLE: their pathogenic relationship. Clin Exp Rheumatol 1998; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/182\">",
"      Perl A, Fernandez D, Telarico T, Phillips PE. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol 2010; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/183\">",
"      Lehmann P, H&ouml;lzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/184\">",
"      Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/185\">",
"      Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/186\">",
"      Ghaussy NO, Sibbitt WL Jr, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001; 28:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/187\">",
"      Parks CG, Cooper GS, Nylander-French LA, et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 2002; 46:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/188\">",
"      Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 2006; 15:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/189\">",
"      Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/190\">",
"      Finckh A, Cooper GS, Chibnik LB, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006; 54:3648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/191\">",
"      Chiou SH, Lan JL, Lin SL, et al. Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus 2004; 13:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/192\">",
"      Wang J, Kay AB, Fletcher J, et al. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis 2009; 68:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/193\">",
"      Wang J, Pan HF, Ye DQ, et al. Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis. Clin Rheumatol 2008; 27:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/194\">",
"      Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/195\">",
"      D'Andrea DM, Coupaye-Gerard B, Kleyman TR, et al. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996; 49:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/196\">",
"      Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94:4220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/197\">",
"      Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/198\">",
"      Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 1970; 49:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/199\">",
"      Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/200\">",
"      Davies KA, Peters AM, Beynon HL, Walport MJ. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 1992; 90:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/201\">",
"      Termaat RM, Assmann KJ, Dijkman HB, et al. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 1992; 42:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/202\">",
"      Schmiedeke TM, St&ouml;ckl FW, Weber R, et al. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 1989; 169:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/203\">",
"      Li QZ, Zhen QL, Xie C, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/204\">",
"      Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/205\">",
"      Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/206\">",
"      Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/207\">",
"      Li JS, Liu MF, Lei HY. Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Clin Immunol Immunopathol 1996; 79:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/208\">",
"      Reichlin M. Cell injury mediated by autoantibodies to intracellular antigens. Clin Immunol Immunopathol 1995; 76:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/209\">",
"      Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol 1993; 100:58S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/210\">",
"      Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992; 90:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/43/37562/abstract/211\">",
"      Reefman E, Kuiper H, Jonkman MF, et al. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) 2006; 45:538.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4669 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37562=[""].join("\n");
var outline_f36_43_37562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H443498\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Geographic and racial distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age at onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Factors affecting disease outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hormonal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immune abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS OF CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cell-surface antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443498\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42695?source=related_link\">",
"      Miscellaneous antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_43_37563="Breast self-exam PI";
var content_f36_43_37563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to do a breast self-exam",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The best time to do a breast self-exam (BSE) is a week after your period ends. If you no longer get monthly periods, you can do the exam any time. Some women do self exams once a month. Others do them less often or not at all. Do whatever you are most comfortable with.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Start by standing in front of a mirror. Place both hands at your sides. Check your breasts for changes in skin color or texture, and check for dents. Note how your nipples look. Some women have inverted nipples, meaning that their nipples point inward instead of out. This is normal as long as the way they look does not change over time.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Lift your hands over your head and turn to the side. Then look at each whole breast in the mirror. If you need to, lift each breast to so you can see the skin under the breast.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Lie down and put your left hand above your head (this flattens the breast and makes it easier to examine). Use your right hand to examine your left breast, starting in the upper breast near the arm pit and going up and down across the breast (like mowing a lawn). Begin to examine the breast by making small circles with your three middle fingers. Use your finger pads at the end of your fingers but not the tips, and move your fingers in circles as if you were tracing the edge of a dime. At each spot on the breast, make three circles: one very light, one a bit firmer into the breast, and one deep in the breast. Then switch hands and do the same thing on the other breast.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          It is normal to feel your ribs in your chest. Abnormal lumps tend to feel firm, have irregular edges, and sometimes feel like they are \"stuck\" to your chest. If you don't know whether a lump is normal or abnormal, see your doctor or nurse.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37563=[""].join("\n");
var outline_f36_43_37563=null;
var title_f36_43_37564="causes bradycardia children";
var content_f36_43_37564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of bradycardia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrinsic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Collagen vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Congenital Heart Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrioventricular canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long QT syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transposition of the great arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wolff Parkinson White syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Myocardial ischemia or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Surgical trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial operations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrinsic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antiarrhythmic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beta-adenergic blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium-channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hypervagotonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breath-holding spells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coughing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esophageal or nasopharyngeal stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increased intracranial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Edrophonium, physostigmine, bethanechol, neostigmine, acetylcholine, hyoscyamine, phenylephrine, methoxamine, morphine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurocardiac syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sleep",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37564=[""].join("\n");
var outline_f36_43_37564=null;
var title_f36_43_37565="Causes of massive hemoptysis";
var content_f36_43_37565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of massive hemoptysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitral stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricuspid endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coagulopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disseminated intravascular coagulation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thrombocytopenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Platelet dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Von Willebrand's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycetoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrotizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fungal or tuberculous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplastic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchial adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchogenic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastatic cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Traumatic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blunt or penetrating chest injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ruptured bronchus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fat embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tracheal-innominate artery fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Goodpasture's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic pulmonary hemosiderosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pulmonary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchiectasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bullous emphysema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Iatrogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchoscopy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Swan Ganz catheter-induced infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary artery rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transtracheal aspiration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangiography",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            A-V malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs or toxins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticoagulants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimellitic anhydride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Solvents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crack cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thrombolytic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broncholithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septic pulmonary emboli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphangioleiomatosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cahill BC, Ingbar DH, Clin Chest Med 1994; 15:147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37565=[""].join("\n");
var outline_f36_43_37565=null;
var title_f36_43_37566="Pediatric acute hip pain and limp algorithm";
var content_f36_43_37566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Child with limp and acute hip pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SCFE: slipped capital femoral epiphysis; WBC: white blood cell.",
"     <br>",
"      * White blood cell count &gt;50,000/microL or positive Gram stain. Children may have septic arthritis without either of these findings.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_43_37566=[""].join("\n");
var outline_f36_43_37566=null;
var title_f36_43_37567="Contents: General health";
var content_f36_43_37567=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General health",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alcohol use",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/46/17122\">",
"           Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/17/37137\">",
"           Patient information: Alcohol poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/21/44371\">",
"           Patient information: Alcohol use ��������� when is drinking a problem? (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39361\">",
"           Patient information: Alcohol use ��������� when is drinking a problem? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/23/4468\">",
"           Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Alternative medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/33/25105\">",
"           Patient information: Alternative medicine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/51/21300\">",
"           Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/29/39378\">",
"           Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Body art",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2610\">",
"           Patient information: Tattoos and body piercings (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cancer screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/40/36481\">",
"           Patient information: Breast cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/59/19379\">",
"           Patient information: Breast cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/63/10227\">",
"           Patient information: Cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8019\">",
"           Patient information: Cervical cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7541\">",
"           Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/34/25123\">",
"           Patient information: Colon and rectal cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25747\">",
"           Patient information: Colon polyps (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/5/9298\">",
"           Patient information: Colon polyps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9698\">",
"           Patient information: Colonoscopy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18611\">",
"           Patient information: Colonoscopy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5570\">",
"           Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/13/11475\">",
"           Patient information: Lung cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/15/6386\">",
"           Patient information: Ovarian cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27874\">",
"           Patient information: Ovarian cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15491\">",
"           Patient information: Pap tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/55/38770\">",
"           Patient information: Prostate cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/27/32176\">",
"           Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical trials",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/16/37121\">",
"           Patient information: What are clinical trials? (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cost of healthcare",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/43/37554\">",
"           Patient information: Medicine brand and generic names (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/61/32726\">",
"           Patient information: Reducing the costs of medicines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/21/6483\">",
"           Patient information: Reducing the costs of medicines (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Environmental toxins",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/37/16978\">",
"           Patient information: Cadmium toxicity (Cadmium poisoning) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/44/17089\">",
"           Patient information: Carbon monoxide (CO) poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/40/22146\">",
"           Patient information: Lead poisoning (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Exercise",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40835\">",
"           Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/42/7844\">",
"           Patient information: Exercise (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/39/20083\">",
"           Patient information: Exercise (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         First aid and CPR",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13281\">",
"           Patient information: Black eye (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/2/6178\">",
"           Patient information: CPR for adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/50/26402\">",
"           Patient information: CPR for children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/51/33586\">",
"           Patient information: Electrical burns (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31569\">",
"           Patient information: Frostbite (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/15/37105\">",
"           Patient information: Heat stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/6/109\">",
"           Patient information: Hypothermia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/51/6962\">",
"           Patient information: Stitches (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/10/42145\">",
"           Patient information: Taking care of bruises (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/11/43185\">",
"           Patient information: Taking care of cuts and scrapes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leaving the hospital",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/16/34050\">",
"           Patient information: Going home from the hospital (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Legal issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/61/25554\">",
"           Patient information: Advance directives (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/21/25939\">",
"           Patient information: Medical care during advanced illness (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Managing medicines",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/49/33554\">",
"           Patient information: Acetaminophen poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/483\">",
"           Patient information: Dealing with side effects from medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/21/26962\">",
"           Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/3/23603\">",
"           Patient information: Drug allergy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/22/4451\">",
"           Patient information: Latest medicines for hepatitis C (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/11/14515\">",
"           Patient information: Latest medicines to prevent blood clots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/43/37554\">",
"           Patient information: Medicine brand and generic names (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/27/21940\">",
"           Patient information: Medicines after a heart attack (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/37/36435\">",
"           Patient information: Medicines after an ischemic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/8/34947\">",
"           Patient information: Medicines for Parkinson disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/35/1587\">",
"           Patient information: Medicines for angina (chest pain) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/22/30052\">",
"           Patient information: Medicines for asthma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/36/17986\">",
"           Patient information: Medicines for atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/41/36499\">",
"           Patient information: Medicines for heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/40/23171\">",
"           Patient information: Medicines for high blood pressure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/41/6803\">",
"           Patient information: Medicines for osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11363\">",
"           Patient information: Narcotic pain medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/13/2262\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/15/40178\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/21/7506\">",
"           Patient information: Prescription drug abuse (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/61/32726\">",
"           Patient information: Reducing the costs of medicines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/21/6483\">",
"           Patient information: Reducing the costs of medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/482\">",
"           Patient information: Serotonin syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/38/12898\">",
"           Patient information: Stevens-Johnson syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/34/32290\">",
"           Patient information: Taking medicines when you're older (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/12/12483\">",
"           Patient information: What you should know about antibiotics (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preparing for surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/52/30530\">",
"           Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preventive healthcare",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/4/42050\">",
"           Patient information: Preventing falls (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/54/867\">",
"           Patient information: Preventive healthcare for older adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1940\">",
"           Patient information: Screening for sexually transmitted diseases (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Quitting smoking",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/13/19670\">",
"           Patient information: Quitting smoking (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/46/18146\">",
"           Patient information: Quitting smoking (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rape",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1509\">",
"           Patient information: Care after sexual assault (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Signs and symptoms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/48/8962\">",
"           Patient information: Acute abdomen (belly pain) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/4/38978\">",
"           Patient information: Daytime sleepiness (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/62/32738\">",
"           Patient information: Dehydration (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/6/22625\">",
"           Patient information: Hiccups (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/51/18226\">",
"           Patient information: Low blood sugar in people without diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/31/36338\">",
"           Patient information: When to worry about a fever (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sunburn",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/30/18913\">",
"           Patient information: Sunburn (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/20/23874\">",
"           Patient information: Sunburn (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/60/33729\">",
"           Patient information: Sunburn prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Travel advice",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16421\">",
"           Patient information: General travel advice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/42/27298\">",
"           Patient information: Staying healthy when you travel (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33122\">",
"           Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/26/38305\">",
"           Patient information: Typhoid fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21187\">",
"           Patient information: Vaccines for travel (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AECA7F8E1D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_43_37567=[""].join("\n");
var outline_f36_43_37567=null;
